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Abstract: 
Epidemiologic and Clinical Profiles of Uterine Cancer in the Gharbiah Province of 
Egypt 
Saad Alshahrani, Ph.D. 
University of Nebraska Medical Center, 2017 
Supervisor: Amr Soliman, M.D, Ph.D.  
Background: Uterine cancer is one of the top-ranking cancers of women with wide 
international variations in incidence rates. Egypt has a lower incidence of uterine cancer 
than other countries in the Middle East. In addition to the international incidence 
variation, there are also wide variations in incidence by rural and urban areas within 
countries. Therefore, this research project focused on the Gharbiah province, north of 
Cairo in the Nile Delta, with the aims of investigating demographic and clinical 
characteristics of uterine cancer, assessing rural/urban variation in incidence rates, and 
evaluating the possible role of hysterectomy in under-estimating the disease incidence in 
this population.   
Methods: Uterine cancer data of 660 cases were obtained from the Gharbiah Population-
based Cancer Registry in Gharbiah, Egypt during the period 1999-2010. The 
hysterectomy data of 1040 cases were abstracted from the main pathologic labs over the 
entire region.  The Egypt 2006 data census was used to determine the total population of 
Gharbiah and the rural and urban subgroups. Crude, age-standardized (ASR), and age-
specific rates were calculated and associated with demographic and clinical 
characteristics of patients. The uterine cancer incidence pre- and post- adjustment for 
hysterectomy prevalence were compared and 95% confidence intervals (CIs) were 
calculated. 
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Results: The results confirmed the low ASR of uterine cancer in Gharbiah, [4.1 per 
100,000 (95% CI: 3.8-4.4)]. The incidence rate significantly increased over the 12-year 
period. The ASR was 2.5 times higher in urban areas compared to rural areas (6.9 and 2.8 
per 100,000), in urban and rural areas, respectively. The prevalence of hysterectomy did 
not have a significant impact on the uterine cancer incidence rate. 
Conclusions: The study confirmed the low incidence rate of uterine cancer in the 
Gharbiah province of Egypt and a statistical significant increase in incidence in recent 
years. Although, the rate of uterine cancer in this population increased over the past 
decade, it is still lower than the corresponding global rates. The lack of evidence about 
the possible role of hysterectomy in lowering of uterine cancer rates adds to the need for 
research to identify the apparent protective factors for uterine cancer in this population.   
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 Chapter 1:  
Background 
Anatomy and Histology of Uterus:  
The uterus is the female muscular organ that lies in the pelvic area between the urinary 
bladder and the rectum. It has a pear shape and it goes through different developmental 
phases during women’s life based on hormonal changes during the menstrual cycles. The 
most important role of the uterus is childbearing and reproduction. The uterus consists of 
three anatomical parts, the fundus, which is the upper part that has a dome shape, the 
corpus, the middle part that involves the body of the uterus, and the cervix uteri that is the 
distal part of the uterus. From a histologic standpoint, the uterus has two layers, the inner 
glandular layer that is called the endometrium and the outer muscular layer that is 
referred to the myometrium.  
Physiology and Hormonal Changes: 
The uterus undergoes regular monthly changes during menstrual cycles occurring 
throughout the childbearing period based on the fluctuations in blood hormonal levels. 
The menstrual cycle is usually about 28 days and has two phases. The first phase is 
known as the follicular or proliferative phase in which ovarian follicles develop and the 
second phase is known as the luteal or secretory phase in which the remaining ovarian 
follicles turn into a corpus luteum. The production of estradiol by the ovarian follicles 
initiates the Luteinizing Hormone (LH) surge, which is followed by ovulation. The LH 
subsequently induces the formation of the progesterone by the stimulation of luteinization 
of the granulosa cells in the ovary. Progesterone later enhances the follicle–stimulating 
hormone (FSH) surge. The luteal phase lasts for 14 days and ends by the menses that 
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lasts for approximately 4-6 days. The occurrence of pregnancy will maintain the 
progesterone and estrogen in high levels. 1,2  
Types of Uterine Cancer:  
There are two types of uterine cancer based on the origin of the tumor. The first type is 
endometrial cancer that arises from the inner layer of the uterus and represents about 90% 
of all uterine cancers. Because the majority of uterine cancers are endometrial in origin, 
uterine cancer is usually referred to as endometrial cancer in most of the literature. The 
second type of uterine cancer is sarcoma that arises from the muscular (myometrium) or 
the supportive tissue of the uterus and represents about 8% of uterine cancer. 3 Other rare 
types of uterine cancer include malignant mixed Mullerian tumor, (MMMT). 4,5   
Pathologic Subtypes and Genomic Classification of Uterine Cancer:  
Based on the sensitivity of the uterine tissue to hormones, endometrial cancers are 
classified into Type 1 and Type 2 tumors. Type 1 tumors are hormone-sensitive lesions 
influenced by high levels of estrogen while Type 2 tumors are less-driven by estrogen. 
Type 1 tumors constitute about 80% of endometrial cancers and are usually diagnosed at 
lower stages than Type 2 tumors. Type 2 tumors, represent 10% of endometrial cancers 
and are diagnosed at late stage and have high rates of recurrence. 6 In addition, based on 
the cell of origin, endometrial cancer could be classified into 7 subgroups: 1) 
endometrioid  (75%–80%) which includes ciliated adenocarcinoma, secretory 
adenocarcinoma, papillary and villoglandular and adenocarcinoma with squamous 
differentiation; 7 2) uterine papillary serous (<10%); 3) mucinous (1%); 4) clear cell 
(4%); 5) squamous cell (<1%); 6) mixed (10%); and 7) undifferentiated. 8,9 Therefore, all 
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cancer cell types that are not driven by estrogen and have poor differentiated carcinoma 
are classified as Type 2 endometrial cancers that include papillary serous carcinoma, 
clear-cell carcinoma, undifferentiated carcinoma, and grade III endometrioid 
carcinoma.10 
Based on genomic studies, endometrial cancer is classified into 4 subtypes, POLE 
ultramutated, microsatellite instability hyper-mutated, copy-number low, and copy-
number high. 11 There is a potential that the recent genomic classification has important 
value in prognostic and therapeutic implications. 11-13 Table1 shows the different 
characteristics of different types of endometrial genomic subtypes.  
Table 1: Characteristics of four genomic classes of endometrioid and serous 
carcinomas 
  POLE 
(ultramutated) 
MSI 
(hypermutated) 
Copy-number 
low 
(endometrioid) 
Copy-number high 
(serous-like) 
Copy-
number 
aberrations 
Low Low Low High 
MSI/MLH1 
methylation 
Mixed MSI 
high<comma> 
low<comma> 
stable 
MSI high MSI stable MSI stable 
Mutation rate Very high (232 
× 10−6 
mutations/Mb) 
High (18 × 
10−6 
mutations/Mb) 
Low (2·9 × 
10−6 
mutations/Mb) 
Low (2·3 × 10−6 
mutations/Mb) 
Genes 
commonly 
mutated 
(prevalence) 
POLE (100%) 
PTEN (94%) 
PIK3CA (71%) 
PIK3R1 (65%) 
FBXW7 (82%) 
ARID1A (76%) 
KRAS (53%) 
ARID5B (47%) 
PTEN (88%) 
RPL22 (37%) 
KRAS (35%) 
PIK3CA (54%) 
PIK3R1 (40%) 
ARID1A (37%) 
PTEN (77%) 
CTNNB1 
(52%) PIK3CA 
(53%) PIK3R1 
(33%) ARID1A 
(42%) 
TP53 (92%) 
PPP2R1A (22%) 
PIK3CA (47%) 
Histological 
type 
Endometrioid Endometrioid Endometrioid Serous, 
endometrioid, and 
mixed serous and 
endometrioid 
Tumor grade Mixed  
(grades 1–3) 
Mixed  
(grades 1–3) 
Grades 1 and 2 Grade 3 
  
 
4 
Progression-
free survival 
Good Intermediate Intermediate Poor 
Reprinted from The Lancet Oncology, Murali,R., Soslow,R.A., Weigelt,B, Classification of 
endometrial carcinoma: more than two types, Copyright (2014), with permission from 
Elsevier14 
Pathogenesis of Uterine Cancer:  
Type 1 and type 2 tumors have different pathogenesis. Type 1 tumors are believed to 
result from high and long exposure to estrogen that increases the probability of 
occurrence of atypical hyperplasia that precedes the development of Type 1 endometrial 
cancer. 6 This type of cancer is usually found in premenopausal young patients compared 
to Type 2 of endometrial cancer that occurs mainly in postmenopausal women. The 
hormonal and genetic mutations and abnormalities could influence the pathogenesis of 
this type. This includes microsatellite instability, K-ras and PTEN mutations, and defects 
in DNA mismatch repair. 15-17   
Although, the molecular pathway of developing type 1 is not clear, tumor suppressor 
gene (PTEN) expressions are identified in the endometrium after prolonged exposure to 
high estrogen levels. 6  
Mutations in the p53 gene are believed to play important role in Type 2 endometrial 
cancer. The mutations in the p53 gene are found in 80-90% of endometrial intraepithelial 
carcinoma (EIC). 18 EIC is the precursor of serous carcinoma (Type 2). 18,19  
The distribution of genetic mutations observed in Type 1 and type 2 tumors in different 
studies is illustrated in table 2 that summarized the result from a review article.   
Table 2: Percentages of Genetic Alteration among the two types of Endometrial 
Cancers  
Genetic Alteration Type 1 Tumor  Type 2 Tumor  
PTEN inactivation Up to 83% 11%  
PIK3CA mutation 26–36%  5%  
KRAS mutation 10–30% 0–10%  
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β-catenin /CTNNB1 mutation 14–44% 0–5% 
Microsatellite instability 20–45% 0–11%  
p53 mutation 10–20% 90%  
HER2/neu amplification 10–30%  18–80%  
p16 inactivation 10%  40–45% 
E-cadherin loss 10–20%  60–90% 
Adapted from “Molecular Profiling of Endometrial Malignancies” by Samarnthai N, 
Hall K, Yeh IT., 2010, Obstetrics and Gynecology International.20 
Tumor Staging and Grading System: 
There are two main systems used for endometrial cancer staging: the Federation 
International de Gynecology and Obstetrics (FIGO) and the American Joint Committee 
on Cancer (AJCC). Both systems represent surgical staging that is based on 
characteristics of the resected tissue from the surgical procedures. Both systems were 
established based on the Tumor size (T), Lymph Node involvement (N) and tumor 
Metastasis to other organs (M). The differences between the two systems are that FIGO 
does not include stage 0 anymore.  The most recent updated versions of these two 
systems consider pathologic and surgical criteria for staging. 21-23 The FIGO staging was 
last revised in 2009 and the AJCC was last revised in 2016. 24 However, the FIGO staging 
is the most commonly used in clinical practice and research (Table 3 and 4).25 
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Table 3: Staging uterine carcinoma: TNM and International Federation of 
Gynecology and Obstetrics (FIGO) Classification Systems.  
Primary tumor (T) (surgical-pathologic findings) 
TNM 
categories 
FIGO 
stages 
Definition 
TX   Primary tumor cannot be assessed 
T0   No evidence of primary tumor 
Tis   Carcinoma in situ (pre-invasive carcinoma) 
T1 I Tumor confined to corpus uteri 
T1a IA Tumor limited to endometrium or invades less than one-half of the 
myometrium 
T1b IB Tumor invades one-half or more of the myometrium 
T2 II Tumor invades stromal connective tissue of the cervix but does not 
extend beyond uterus 
T3a IIIA Tumor involves serosa and/or adnexa (direct extension or 
metastasis) 
T3b IIIB Vaginal involvement (direct extension or metastasis) or 
parametrial involvement 
T4 IVA Tumor invades bladder mucosa and/or bowel mucosa (bullous 
edema is not sufficient to classify a tumor as T4) 
Regional lymph nodes (N) 
TNM 
categories 
FIGO 
stages 
Definition 
NX   Regional lymph nodes cannot be assessed 
N0   No regional lymph node metastasis 
N1 IIIC1 Regional lymph node metastasis to pelvic lymph nodes 
N2 IIIC2 Regional lymph node metastasis to para-aortic lymph nodes, with 
or without positive pelvic lymph nodes 
Distant metastasis (M) 
TNM 
categories 
FIGO 
stages 
Definition 
M0   No distant metastasis 
M1 IVB Distant metastasis (includes metastasis to inguinal lymph nodes 
intraperitoneal disease, or lung, liver, or bone. It excludes 
metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or 
adnexa.) 
Used with the permission of the American Joint Committee on Cancer (AJCC), 
Chicago, Illinois. The original source for this material is the AJCC Cancer Staging 
Manual, Eighth Edition (2017) published by Springer New York, Inc.24 
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Table 4: staging of uterine sarcoma FIGO and TNM Systems:  
Leiomyosarcoma and Endometrial Stromal Sarcoma  
Primary tumor (T) 
TNM 
categories 
FIGO 
stages 
Definition 
Leiomyosarcoma and endometrial stromal sarcoma 
TX   Primary tumor cannot be assessed 
T0   No evidence of primary tumor 
T1 I Tumor limited to the uterus 
T1a IA Tumor 5 cm or less in greatest dimension 
T1b IB Tumor more than 5 cm 
T2 II Tumor extends beyond the uterus, within the pelvis 
T2a IIA Tumor involves adnexa 
T2b IIB Tumor involves other pelvic tissues 
T3 III¶ Tumor infiltrates abdominal tissues 
T3a IIIA One site 
T3b IIIB More than one site 
T4 IVA Tumor invades bladder or rectum 
Adenosarcoma 
TX   Primary tumor cannot be assessed 
T0   No evidence of primary tumor 
T1 I Tumor limited to the uterus 
T1a IA Tumor limited to the endometrium/endocervix 
T1b IB Tumor invades to less than half of the myometrium 
T1c IC Tumor invades more than half of the myometrium 
T2 II Tumor extends beyond the uterus, within the pelvis 
T2a IIA Tumor involves adnexa 
T2b IIB Tumor involves other pelvic tissues 
T3 III¶ Tumor involves abdominal tissues 
T3a IIIA One site 
T3b IIIB More than one site 
T4 IVA Tumor invades bladder or rectum 
Regional lymph nodes (N) 
TNM 
categories 
FIGO 
stages 
Definition 
Leiomyosarcoma and endometrial stromal sarcoma 
NX   Regional lymph nodes cannot be assessed 
N0   No regional lymph node metastasis 
N1 IIIC Regional lymph node metastasis 
Adenosarcoma 
NX   Regional lymph nodes cannot be assessed 
N0   No regional lymph node metastasis 
N1 IIIC Regional lymph node metastasis 
Distant metastasis (M) 
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TNM 
categories 
FIGO 
stages 
Definition 
Leiomyosarcoma and endometrial stromal sarcoma 
M0   No distant metastasis 
M1 IVB Distant metastasis (excluding adnexa, pelvic and abdominal 
tissues) 
Adenosarcoma 
M0   No distant metastasis 
M1 IVB Distant metastasis (excluding adnexa, pelvic and abdominal 
tissues) 
Used with the permission of the American Joint Committee on Cancer (AJCC), 
Chicago, Illinois. The original source for this material is the AJCC Cancer Staging 
Manual, Eighth Edition (2017) published by Springer New York, Inc.24 
Symptoms and Diagnosis of Uterine Cancer:  
Uterine cancer has early symptoms compared to other types of gynecological cancers. 
About 90% of women diagnosed with uterine cancer presented with abnormal vaginal 
bleeding. 26 It is the most common symptom that can lead to early diagnosis. 6  
The diagnosis of uterine cancer can be established based on the histologic examination of 
uterine specimens. The uterine specimens can be obtained through different methods with 
different accuracy. Table 5 shows the accuracy of different methods used. In addition, 
some non-invasive methods like transvaginal ultrasound can be used for diagnosis.27 
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Table 5: Accuracy of endometrial histologic methods for diagnosing neoplasia. 
 Method  Diagnostic Accuracy (%)  Tissue Insufficient for 
Diagnosis (%) 
 Aspiration 
  
 Pipelle 95–98 9 
 Endocell 95–98 11 
 Vabra 95–98 26 
 Isaacs cell sampler 95–98 30 
 Pistolette 95–98 13 
 Brushing 
  
 Endoscann 100 36 
 Biopsy 
  
 Kevorkian 97 10 
 Accuracy of endometrial histologic methods for diagnosing neoplasia. Adapted from 
“Endometrial Hyperplasia and Neoplasia: Definition, Diagnosis, and Management 
Principles,” by Mutter, G, Ferenczy, A, 2008, Glob Libr Womens Med, 28. Reprinted 
with permission. 
Treatment of Uterine Cancer:  
Usually the first option of treatment of uterine cancer is surgery. The surgery of removing 
the uterus is called hysterectomy. The surgery may include some other organs. 
Hysterectomy with salpingo-oophorectomy will remove the uterus, fallopian tubes, and 
ovaries. Radical hysterectomy will include the removal of the uterus, fallopian tubes, 
ovaries, and cervix. The surgery may include removing regional lymph nodes. Based on 
the cancer type and the condition of the patient surgery may combine with adjuvant 
therapy to kill the remaining cancer cells in the body. This includes the chemotherapy, 
radiation therapy and hormonal therapy. Figure1 shows the different modalities that can 
be used to determine the treatment types for endometrial cancer patients based on 
National Comprehensive Cancer Network (NCCN) Guideline Version 1.2017. 
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Figure 1: Treatment options for uterine cancer based on the surgical stages 
 
 
Adapted from NCCN Clinical Practice Guidelines in Oncology (Uterine Neoplasms), 
National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2017, 
(www.nccn.org).  
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Risk Factors 
There are different factors that may play role in increasing the risk of uterine cancer. It 
includes age, low parity, family history of uterine cancer, obesity, diabetes mellitus, 
hormone replacement therapy, tamoxifen and age of menarche and menopause.  
Age: 
Since the majority (approximately 80%) of uterine cancers are diagnosed among 
postmenopausal women, older age is a risk factor for endometrial cancer. The peak age-
specific incidence rate in the U.S. and globally is in the age groups of 50-65 years. 29,30   
Parity:  
Women with low parity are known to be at higher risk for uterine cancer compared to 
women with high parity.  A meta-analysis study that included 69,681 patients from ten 
prospective studies, 35 case control studies and one pooled analysis have confirmed the 
significant inverse relationship of the parity with uterine cancer (RR= 0.69 and 95% CI 
0.65-0.74). Furthermore, it confirms that the risk is decreasing with high number of the 
parity. Nulliparous carries a strong risk for uterine cancer. 31 However, some factors 
related to the infertility that associated with the nulliparity may influence the endometrial 
cancer e.g. (polycystic ovary syndrome). 32 Furthermore, short intervals between 
pregnancies and until menopause and high parity are associated with reduced risk for 
uterine cancer. 33-35   
Family History and Genetic Disorder:  
Research studies have shown a positive association between family history of uterine 
cancer and increased risk in unaffected female relatives. The odds ratio has been 
estimated as 2.1 to 2.8 in different studies. 36,37 However, some studies found that women 
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with family history of uterine cancer will have only small risk for uterine cancer. 38,39 In 
addition, hereditary non-polyposis colorectal cancer (HNPCC) syndrome carries higher 
risk for unaffected female family members. 40,41  
Obesity:  
There are different ways to determine the obesity. However, the body mass index (BMI) 
was recognized and adopted by many accredited agency such as World Health 
Organization (WHO) and American Heart Association (AHA). 42,43 The adult normal 
weight considered when (BMI ≥18.5 to 24.9 kg/m2), overweight when (BMI ≥25 to 29.9 
kg/m2), obesity when (BMI of ≥30 kg/m2) and severe obesity when BMI ≥40 kg/m2). 42,43  
There has been a consistency among several studies that linked uterine cancer to obesity. 
The relative risk of uterine cancer associated with the obesity was ranging from 2 to 10 in 
many studies using different types of measurement e.g. BMI, 44-49 body weight, 38,50-52 
waist-to-thigh circumference ratio, 53 and waist-to-hip circumference ratio. 54,55 While the 
risk found to be high and consistent in the postmenopausal women, some study skeptical 
about the association of obesity and uterine cancer in premenopausal women.37 
Obesity and overweight can lead to insulin resistance, ovarian androgen excess, 
anovulation, and chronic progesterone insufficiency in premenopausal women. 49 In 
postmenopausal women, conversion of the androgens in the adipose tissue through the 
aromatization can also lead to higher levels of circulating estrogens. These variations in 
estrogen levels may affect the cells of breast and endometrium by preventing apoptosis 
and stimulating angiogenesis by increasing cellular proliferation. 56  
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Diabetes Mellitus: 
Glycemic load is considered a probable factor that may increase the risk of uterine 
cancer. 57-59 However, some studies claim that the risk is linked to the comorbidity of 
obesity. 60,61 Different studies found the risk of diabetes was independent with RR= 2.0, 
95% CI (1.1-3.6). 50   
There are different mechanisms that explain the potential effect of hyperglycemia on 
uterine cancer. The long period of hyperglycemic exposure can lead to increases in 
insulin-like growth factor 1 (IGF-1). IGF-1 enhances the cells growth, decreases cell 
death, and stimulates cell duplication of uterine cancers. 59,62 Moreover, oxidative stress 
can be increased by the glycemic overload which triggers uterine cancer. 56  
Hormone Replacement Therapy (HRT):  
HRT is frequently used by women in developed countries to treat menopausal symptoms. 
It is taken to treat the deficiency in the circulating estrogen and progesterone hormones in 
postmenopausal women. A meta-analysis study that included 30 studies concluded that 
the RR was 2.3 (95% CI 2.1-2.5), in women using estrogen compared to the nonusers. In 
addition, women using estrogen for 10 or more years could increase the relative risk to 
9.5. However, the risk of uterine cancer was decreased when estrogen combined with 
progestin. 63,64 However, the Women’s Health Initiative has concluded that the risk of 
using combined estrogen plus progestin was exceeding the benefit.65 
The HRT (unopposed estrogen) induces the mitotic stimulation of the endometrium with 
partial shedding. 66 The adding of the progesterone will alleviate the effect of the estrogen 
by neutralizing the receptor of estrogen and enhance the process of the estradiol 
metabolisation. 67   
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Tamoxifen: 
Tamoxifen is a trans-isomer of a triphenylethylene derivative drug that used to prevent 
and treat breast cancers that are hormone-receptor positive. It prevents the estrogen to 
bind with the receptor by attaching with the hormone receptor in the cancer cell. Several 
studies revealed that the odds ratio of the association of Tamoxifen use and uterine cancer 
was ranging from 2.5 to 9.5 based on the duration of usage of Tamoxifen. 68-72 However, 
another study has criticizing the association of Tamoxifen and uterine cancer since the 
biases may affect their inferences. 73  
Tamoxifen works as anti-estrogen on breast tissue, however it works as an estrogen on 
the endometrium. 74 Therefore, Tamoxifen enhances the estrogenic effect on the 
endometrium which leads to growth of the lining layer of uterus and increases the risk of 
developing cancer. 74  
Age of Menarche and Menopause:  
Age of menarche and menopause has been associated with the risk of endometrial cancer 
in different studies. Girls with early age of menarche i.e. before age 11 or 12 have a high 
risk of uterine cancer with the RR ranging between 1.5 to 5. 38,44,46,50 Longer periods 
between menarche and menopause have been associated with a higher risk of endometrial 
cancer and shorter periods have been associated with reduced risk. 38,44,46,75  
The mechanism of increasing risk have been associated with longer periods of exposure 
to estrogen and related enhancement of proliferative factor that lead to endometrial 
cancer.76 
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Protective Factors  
Some factors have been found to be protective against uterine cancer. These factors 
included contraceptive hormones, smoking, physical activates and coffee.   
Contraceptive hormones: 
Contraceptive hormones are synthetic estrogen and progestin hormones that are used to 
prevent the pregnancy. They can be administered in different forms e.g. oral pill, skin 
patch or an implant. 77 They have been reported in several studies including a meta-
analysis study involved more than 27,276 women that the using of oral contraceptive 
drugs showed a decline the uterine cancer by 30%.37,78-81 The protective effect of these 
types of drugs were increased simultaneously with the increasing of usage duration.81 
The protective effect of the hormonal contraceptive drugs resulted from the suppression 
effect of progestin on the endometrial proliferation. 82,83   
Smoking: 
Although cigarette smoking is well-known to be harmful to health, it has been linked to 
reduction in uterine cancer risk that was confirmed by a meta-analysis. 84 However, these 
benefits were not conclusive since some studies limit the protective effect on the current 
but not the ex-smokers. 85,86 In contrast, another study claims that the ex-smokers have 
greater protective effect. 87  
The protective effect is believed to be due to the enhancement effect of smoking on 
estrogen metabolism in the liver, which reduces the risk of uterine cancer development. 88 
In addition, smoking women may reach the age of menopause earlier than non-smokers 
and consequently have less exposure to estrogen. 89  
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Physical activity: 
Some studies found that limited physical activity increases the risk of uterine cancer, after 
adjusting for obesity and caloric intake. 90,91 However, some studies claimed that 
reduction of uterine cancer risk is not directly attributed to the physical exercise. 92 
Physical activity has been suggested as a possible protective factor for uterine cancer 
since it enhances body oxygen uptake and regulates and maintains body metabolism that 
could in turn minimize insulin levels and reduce insulin resistance as well. 93 Moreover, 
physical activity can reduce estradiol levels by increasing sex hormone binding globulin 
(SHBG) and ultimately reduce uterine cancer risk. 94 Therefore, physical activity reduces 
estradiol by enhancing estrogen metabolism or indirectly by reducing body fat stores. 95  
Coffee:  
A consensus among many studies showed that coffee consumption has a protective effect 
against uterine cancer. 96-101 A two meta-analysis studies published in 2008 and 2012 
concluded a significant protective effect of coffee consumption against uterine cancer. 
102,103  
Coffee has strong antioxidant effect through enhancing insulin sensitivity and increasing 
SHBG levels. 100,103 In addition, promoting estradiol elimination and preventing estradiol-
mediated carcinogenesis of uterine cancer cells could result from enhanced liver enzymes 
as an effect of caffeine and bioactive compounds of the coffee.100 
These risk and protective factors for uterine cancer have different magnitudes of risk 
which are presented in Table 6, as adapted from the American Cancer Society Guidelines 
for Early Uterine Cancer Detection88,104,105 However, these risk and protective factors 
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may not be applicable to all populations since all of these studies were conducted in 
Western and East Asian countries.  
Table 6: Relative risk of demographic, hormonal, medical and lifestyle related to 
uterine cancer 
Risk factor Relative risk (RR) 
 
Aging  Women 50- to 70-years-old have a 1.4 
percent risk of endometrial cancer 
Unopposed estrogen therapy 2 to 10 
Tamoxifen therapy 2 
Late menopause (after age 55) 2 
Nulliparity 2 
Polycystic ovary syndrome (chronic 
anovulation) 
3 
Obesity 2 to 4 
Diabetes mellitus 2 
Lynch syndrome (hereditary 
nonpolyposis colorectal cancer) 
22 to 50 percent lifetime risk 
Cowden syndrome 13 to 19 percent lifetime risk 
Physical activity  0.73 to 0.75 
Coffee 0.64 to 0.87 
Reproduced with permission from: Canto MI. Chromoendoscopy. In: UpToDate, Post 
TW (Ed), UpToDate, Waltham, MA. (Accessed on 01/04/2017.) Copyright © 2017 
UpToDate, Inc. For more information visit www.uptodate.com.  88,104  
Screening of Uterine Cancer: 
Unfortunately, there is no efficient or cost-effective way for population screening for 
uterine cancer. 4 However, transvaginal ultrasonography (TVUS), endometrial aspiration 
biopsy and endometrial curettage can help in early detection of uterine cancer in women 
with high risk. 104,106 Because of the periodic variations in endometrium thickness in 
premenopausal women, screening and early detection of cancer are difficult in this age 
group. Therefore, TVUS in the premenopausal is not sensitive while it has the same 
sensitivity of endometrial biopsy in the postmenopausal women. 107,108  
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Global Epidemiology of Uterine Cancer:  
Global and the U.S Epidemiology of Uterine Cancer 
Global Incidence & Mortality  
According to 2012 Globocan,  uterine cancer was ranked as the fifth most common 
cancer for women worldwide after breast, colorectum, cervical, and lung cancers. 109 The 
global average age-standardized incidence and mortality rates of uterine cancer were 8.2 
and 1.8 per 100,000, respectively. The uterine cancer has different incidence distribution 
in different regions of the world. It is the most common gynecologic malignancy in 
developed countries, whereas it is the second most common gynecologic malignancy in 
developing countries after cervical cancer. 109 In general, high-income countries show 
high incidence of uterine cancer while low-income countries have a low incidence of the 
disease. 110 For example, North America and Central and Eastern Europe have the highest 
incidence of uterine cancer in the world. 109In contrast, some regions in Africa show the 
lowest incidence rates in the world. 110-112 The world mortality ASR was 1.7 in 2012.  The 
mortality ASR of uterine cancer has some variations across the world. The WHO 
European Region has the highest mortality rate of 2.6 per 100.000 followed by the 
Americas WHO Regional Office with 2.0 among all six WHO regions, the lowest 
mortality ASR of 1 per 100.000 was reported in the WHO Region of the South East Asia. 
113 The survival rate of uterine cancer in high-income countries is higher than the rate in 
lower income countries. 112 For example, the five-year survival rate in the U.S was 89% 
and in all developed countries was 82% compared to 61% in Sub-Saharan Africa and 
67% in all developing countries.112 
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The variations in uterine incidence and mortality rates across the world can be explained 
by differences in exposure to risk factors and different levels of access to health care. For 
example, low parity and obesity are common in Western women. The use of Tamoxifen 
and oral estrogen replacement therapy are higher in developed countries compared to 
developing countries. Early diagnosis of uterine cancer in high-income countries due to 
better access to healthcare and receiving the appropriate treatment have resulted in a good 
survival rates. On the contrary, late presentation of the disease with limited access to 
diagnostic and treatment facilities may explain the poor survival rate of uterine cancer in 
low-income countries.  
U.S. Incidence & Mortality  
Uterine cancer is the 4th most common type of female cancer in the United States after 
breast, lung and colorectal cancers. In 2013, the age-standardized incidence and mortality 
rates were 26.4 and 4.6 per 100,000, respectively. The uterine cancer incidence rate in the 
U.S. peaked in 1970 followed by a steady decline through the 1980s. 30 Between 1992 
and 2002, the incidence rate was fairly steady (24.4 to 24 per 100,000), but the rate has 
slightly increased since 2002. The incidence rate trend is similar for both younger (20-49 
years) and older (50+ years) population. The incidence rate of uterine cancer is higher 
among white women compared to African-American and Hispanic women while the 
mortality rate was lower among white women compared to African-American and 
Hispanic women.114-118 
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Egypt Overview: 
Egypt Health System 
Egypt is one of the highest populated countries in North Africa. In 2013, the projected 
population of Egypt was 86 million, 50% of them were below 25 years of age. About 
97% of the populations live in 4% of the total area of Egypt. 119,120 The health care system 
in Egypt is managed and financed by different sectors. This includes public government 
sectors which include ministries of health, education, the military, and police. In addition, 
non-governmental organizations, clinics runs by faith based facilities and private health 
sectors, play an important role in health services. Egypt has a wide spread infrastructure 
of primary health care clinics within 3 kilometers of any residential area in the country.119 
Gharbiah Population Cancer Registry:  
In the Gharbiah province a population-based cancer registry was founded in 1998 as a 
project of the Middle East Cancer Consortium. The registry covers the Gharbiah province 
in the center of Nile delta, an area of 1,948 Km and a population of 4,011,320.  The 
registry is located in Tanta city. The registry aims to employ an active registration from 
all the clinics, labs and hospitals of the provinces and from death certificates.  
 Uterine Cancer in Egypt  
In 2012, the age-standardized incidence rate of uterine cancer in Egypt was 3.8 per 
100,000 compared to the global incidence of 8.2 per 100,000. 109 Uterine cancer was 
ranked as the ninth most common cancer of women in Egypt. The initial report of the 
Middle East Cancer Consortium (MECC) for the period 1996-2001 showed that Egypt 
has the lowest incidence of uterine cancer in the region. The incidence rate of uterine 
cancer was lowest in Egypt 3.5 per 100.000 compared to other populations such as Israeli 
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Jews (13.8 per 100.000), Cypriots (11.8 per 100.000), Israeli Arabs (8.7 per 100.000), 
and Jordanians (5.8 per 100.000). 121 In addition, the low stage at diagnosis of uterine 
cancer is high compared to other female cancers in Egypt. With urbanization, life style 
changes are increasing the risk of various types of cancer including hormonally driven 
cancers such as uterine cancer.  Although the risk of uterine cancer is believed to be 
relatively low in Egypt, there seem to be considerable geographic variations in the 
incidence rate of uterine cancer.   
According to a study from the Gharbiah Cancer Registry, the incidence of gynecological 
cancer (ovary, uterine, and cervical) was higher in urban than in rural areas. 122 Uterine 
cancer showed the highest urban–rural incidence rate ratio (IRR = 6.07, 95% CI = 4.17, 
8.85). Also in the advanced age group of urban women the incidence of uterine cancer 
was high compared to women in rural areas. 122 The significant findings of this study that 
shows urban areas have a higher incidence of gynecological cancers compared to rural 
areas would suggest some differences in environmental hormonal compounds across the 
two different areas. However, there may be some factors that affect the overall estimation 
of uterine cancer incidence. Consequently, the variation in these factors among different 
populations would explain the discrepancies in the uterine incidence.  
There are some factors that may lead to variations in uterine cancer across different 
geographic regions or populations. Different risk factors may result in variation of uterine 
cancer incidence. 123 The availability, affordability and accessibility of the health care 
may influence the variation in uterine cancer incidence. In addition, the quality of cancer 
registry plays an important role in the estimation of cancer incidence. The cancer 
incidence can be underestimated or overestimated by failure to determine the population 
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at-risk. For example, the population at risk of uterine cancer should not include women 
with removed uterus (hysterectomy).  Hysterectomy is the surgical removal of the uterus. 
It is considered one of the most frequent surgeries for women. For example, about 88%, 
81%, and 78% of all hysterectomy procedures were done for nonmalignant diseases in 
the US, 124 Germany125 and Sweden126 respectively. Leiomyoma, endometriosis and 
genital prolapse are the most common diseases for which hysterectomy may be used as a 
treatment. In Egypt, there is no clear data about the prevalence of hysterectomy and the 
indication of this surgery in the country. However, there is an impression that there has 
been an overuse and a malpractice of hysterectomy by clinicians and lab workers in 
Egypt.  
There are many studies that show distortions of rate ratios of uterine cancer were changed 
dramatically by adjusting for hysterectomy. The Black women in the U.S have the 
highest prevalence of hysterectomy compared to Hispanic and non-Hispanic white 
women. After adjusting for the hysterectomy effect, the incidence rate of uterine cancer 
was increased in all racial groups. However, the highest increase after adjustment for 
hysterectomy were in U.S. Black women which minimized the gap in uterine cancer 
incidence rates among all groups. 127 Another studies125, 128 supporting this finding and 
they found that the hysterectomy correction has different effect on incidence rate of 
uterine cancer in different geographical regions of the U.S. For example, the 
hysterectomy correction has high impact on rates in the south compared to other regions 
of the U.S. 117 Therefore, accounting for hysterectomy is an important measure to have 
accurate estimate of uterine cancer incidence rate.  
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Goal of the Dissertation Projects:  
Uterine cancer is one of the top-ranking cancers of women with wide international 
variations in incidence rates. Egypt has a lower incidence of uterine cancer than other 
countries in the Middle East. In addition to the international incidence variation, there are 
also wide variations in incidence by rural and urban areas within countries. Women in 
Egypt are exposed to variable levels of hormones and have variable access to medical 
care in rural and urban areas.  Therefore, this research project focused on the Gharbiah 
province, the region with the only population-based cancer registry in the country, with 
the aims of investigating demographic and clinical characteristics of uterine cancer, 
assessing rural/urban variation in incidence rates, and evaluating the possible role of 
hysterectomy in under-estimating the disease incidence in this population.   
There is gap in knowledge of uterine cancer in Egypt. The low incidence rate of uterine 
cancer in Gharbiah region compared to the regional countries is an interesting 
observation to study. It is important to know the characteristics of the uterine cancer in 
the population of Gharbiah region. This will help us to generate a hypothesis about the 
low incidence of uterine cancer in this region. It is important to investigate this low 
incidence rate and examine some factors that may affect the calculation. 
Investigating the potential factors that may lead to low presentation/incidence of uterine 
cancers in Egypt compared to the surrounding countries would help to understand the 
uterine cancer incidence rate variations. Changes in risk factors of uterine cancer e.g. 
obesity and fertility rates, may explain some of the disparities in uterine cancer across the 
regions. There is an impression of an excessive hysterectomy rate in Egypt that may 
affect the validity of the uterine cancer incidence rate. Therefore, it is worthwhile to study 
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the impact of hysterectomy prevalence on the uterine cancer incidence rate in this 
population. This will help to estimate the actual magnitude of the uterine cancer 
incidence rate.  
Project Aims and Hypothesis:  
Aim1:  
To examine the incidence of uterine cancer over the study period and characterize the 
demographic and clinical profiles of patients residing in the Gharbiah province of Egypt 
during the period of 1999-2010. 
 Hypothesis:  
The uterine cancer incidence rate was increasing over the time in Gharbiah.  
Aim 2:  
To investigate the regional variations (rural vs. urban) of uterine cancer by demographic 
characteristics, incidence rate and clinical presentations.   
 Hypothesis:  
The urban women in Ghrabiah have high incidence rate of uterine cancer compared to the 
rural women.  
Aim 3:  
To quantify the impact of hysterectomy rate on the incidence rate of uterine cancer in 
Gharbiah province of Egypt.  
 Hypothesis:  
The uterine cancer incidence rate was underestimated by the high prevalence of 
hysterectomy in Gharbiah.  
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Chapter 2: 
Changes in Uterine Cancer Incidence Rates in Egypt during the Period of 
1999-2010 
Background: 
Globally, uterine cancer is one of the top-ranking cancers that affects women. 109,113 
Endometrial cancer arises from the inner layer (endometrium) of the uterus, the origin of 
approximately 90% of uterine cancers, followed by uterine sarcoma that arises from the 
outer layer (myometrium) (8%) and less frequent types of cancer (2%). 
According to the latest figures of the International Agency for Research on Cancer 
(Globocan 2012), corpus uteri cancer ranks as the fifth most common women’s cancer 
worldwide after breast, colorectal, cervix uteri and lung cancers. 29,109 Globocan reported 
the aggregate age-standardized incidence and mortality rates of corpus uteri cancer as 8.2 
and 1.8 per 100,000, respectively. 109 Uterine cancer has a different incidence distribution 
in different regions of the world. It is the most common gynecologic malignancy in 
developed countries and the second most common gynecologic malignancy in developing 
countries after cervical cancer. 109,129   North America and Central and Eastern Europe 
have the highest incidence of corpus uteri cancer in the world. 29,109 In contrast, some 
regions in Africa show the lowest incidence rate in the world. 110-112  
The variation in uterine cancer incidence rates across the world can be explained by 
differences in exposure to risk factors and different levels of healthcare in the different 
regions. 130  
Based on Globocan, corpus uteri cancer is ranked as the tenth most common cancer 
among women in Egypt. According to the Middle East Cancer Consortium (MECC) 
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Report of 2006, the incidence rate of uterine cancer in Egypt (3.5/100,000) is the lowest 
compared to other countries in the Middle East: Israeli Jews (13.8/100,000), Cypriots 
(11.8/100,000), Israeli Arabs (8.7/100,000) and Jordanians (5.8/100,000). 121 In addition, 
the low stage at diagnosis of uterine cancer is high compared to other female cancers in 
Egypt. 121  
This study incorporated the most recent data collected by the Egyptian registry after the 
published report on the data of 1999-2002. We aimed at verifying the suspected 
increasing incidence rate of uterine cancer and characterizing the demographic and 
clinical profiles of patients residing in the Gharbiah province of Egypt during the period 
of 1999-2010. 
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Methods: 
The Study Population 
The study included the primary uterine cancers that were diagnosed in the Gharbiah 
province and collected by the Gharbiah Population-based Cancer Registry (GPCR) from 
January, 1999 through December, 2010. Data were abstracted from all uterine cancer 
cases included in the registry for the study period. The registry was founded in 1998 as a 
project of the Middle East Cancer Consortium. The Gharbiah Cancer Society is the home 
of GPCR in Tanta, which is the capital city of Gharbiah Province in the center of the Nile 
delta region. The registry uses the International Agency for Research on Cancer (IARC)’s 
software CanReg4 for registry the cases.  The data were actively collected from all 
hospitals and pathologic labs of Gharbiah Province. In addition, patients seeking medical 
care outside the Gharbiah Province are tracked and their data are abstracted and included 
in the registry.  
The Gharbiah province is about 100 km north of Cairo in the Nile delta region. It is the 
tenth largest province in Egypt with a total area of 1,948 Km². It consists of 8 districts. 
These include: El-Mahalla El-Kubra, Kafr El-Zayat, Samannoud, Tanta, Zifta, El-Santa, 
Kotoor and Bassyoun. The total population of Gharbiah Province according to the 
Egyptian census of 2006 was 4,011,320 individuals that represent 5.5% of Egypt’s total 
population. The study was approved by the Institutional Review Board (IRB) at 
University Nebraska Medical Center (UNMC) and Gharbiah Cancer Center Ethics 
Committee.   
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Data Collection:  
Cases were coded in the registry based on the third edition of International Classification 
of Diseases for oncology, (ICD-O-3) coding systems. Cases included C54.0 – C54.9 
(Corpus Uteri Cancer) and C55.9 (Uterus, NOS Cancer). There were 660 cases of uterine 
cancer reported during the period of 1999 through 2010 in Gharbiah Province. The 
demographic and clinical characteristics of the cases that were abstracted included 
registration number of the patients, age, marital status, number of children, place of 
residence, smoking status, occupational status, date and basis of diagnosis, tumor 
topography, tumor morphology, tumor stage, tumor grade, and treatment. The population 
data of the latest Egyptian census of 2006 were obtained from the data of the Central 
Agency for Public Mobilization and Statistics (CAPMAS). 131    
Data management and statistical analysis:  
The histopathologic tumor types were grouped into four types based on the 
histopathologic grouping of the International Agency for Research on Cancer (WHO) 
used in Cancer Incidence in Five Continents Volume IX (CI5). 132  
The Uterine cancer morphology codes were grouped into four main subgroups. These are 
carcinoma (8010-8574, 8576), sarcoma (8800-8811, 8830, 8840- 8921, 8990-8991, 9040- 
9044, 9120-9133, 9150, 9540-9581), other specified malignant neoplasm and unspecified 
malignant neoplasm (8000-8005). Carcinoma was divided into adenocarcinoma (8140-
8141, 8190-8211, 8230-8231, 8260-8263, 8310, 8380, 8382-8384, 8430, 8440-8490, 
8510, 8560, 8570-8574, 8576), other specified carcinoma and unspecified carcinoma 
(8010-8035).  
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Tumor grades were classified into four grades: Grade I, for well differentiated, Grade II, 
for moderately differentiated, Grade III, for poorly differentiated, and Grade IV, for 
undifferentiated anaplastic tumors and lastly the Unspecified Grade. Tumor stages were 
grouped into four stages: local, regional, distal and un-staged. 
The incidence rate (IR) was calculated by dividing the number of events (E) by the total 
number in the population at risk (P) per 100,000 women. The 95% confidence interval 
(CI) was calculated using the following formula: CI= IR±1.96 × IR/√E and the 95% CI of 
rate ratio calculated by using CI = exp [In (IR1/IR2)] ± 1.96 × √ (1/E1 + 1/E2). The 
Egyptian census of 2006 was used to determine the number of women at risk.  
The incidence rate of uterine cancer was calculated for both pre and postmenopausal 
women.  The women with age of 50 years old or older were considered post-menopause 
and the women younger than 50 years old were considered pre-menopause. Due to the 
low number of cases, the incidence rates were compared over the three periods: 1999 to 
2002, 2003 to 2006 and 2007 to 2010. The crude incidence rate was used to compare the 
incidence of uterine cancer over the entire time frame of the study to the initial incidence 
in the period of 1999 to 2002. The person-years at risk was calculated over the 12 year 
period based on the total population of Gharbiah women in the census of 2006. The world 
standards population (WHO 2000) was used to calculate the age-standardized rate.  
Chi-square tests and t-tests were used to test the associations of categorical and 
continuous variables respectively. For all the analyses, a two-sided p-value of ≤0.05 was 
considered statistically significant. SAS version 9.4 (SAS Institute Inc., Cary, NC) was 
used in all statistical analysis.  
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Result:  
There were 660 women diagnosed with primary uterine cancer in the Gharbiah province 
during the period of Jan 1999 through December 2010. Table 7 shows the distribution of 
demographic and clinical characteristics of the patients included in this study. About 83% 
of patients were postmenopausal and 54% lived in urban areas. Most patients (93%) were 
diagnosed based on the histologic diagnosis. However, less than 5% of patients were 
diagnosed with uterine cancer based on the death records only. About 91% of the patients 
had corpus uteri cancer and 9% were had the diagnosis of uterus NOS (not otherwise 
specified). Adenocarcinoma and other carcinomas, comprised 80% of the patients. 
Sarcoma represented 11% of the tumors and 9% of all tumors were “unspecified 
malignant neoplasms”. Surgery alone was the most offered treatment in 48% of treated 
cases, followed by surgery and adjuvant radiotherapy in 19% of the patients who had 
treatment information reported. Treatment data showed that 23% of the patients either did 
not receive any kind of treatment because they were not fit for the treatment or the 
treatment was not available or affordable. In addition, 27% of all patients’ treatment data 
was missing because the treatment data was not available in the registry from the 
beginning, which resulted in “missing” in all of those patients.  
The overall crude incidence rate of uterine cancer in Gharbiah was 2.8 per 100,000 with 
95% CI (2.6-3.0). The age standardized incidence rate was 4.1 per 100,000 with 95% CI 
(3.8-4.4).  Unsurprisingly, the crude incidence rate of uterine cancer was 15.9 per 
100,000 in post-menopausal women with 95% CI (14.6-17.3) whereas the pre-
menopausal women were only 0.57 per 100,000 and 95% CI (0.46-0.67). The crude rate 
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ratio was 28.1 and 95% CI (23.0-34.4). Therefore, the postmenopausal women had 28.1 
times the odds to develop uterine cancer compared to premenopausal women.   
  
 
32 
Table 7: Demographic and Clinical Characteristics of Uterine Cancer patients 
(n=660) in Gharbiah Province between 1999 and 2010. 
  
Variables 
  
Frequency Percent 
95% CI 
LL UL 
Menopausal Status 
Pre-Menopause 115 17.4 14.5 20.3 
Post-Menopause 545 82.6 79.7 85.5 
Residential Status 
Urban 355 53.8 50.0 57.6 
Rural 305 46.2 42.4 50.0 
Periods 
1999-2002 154 23.3 20.1 26.6 
2003-2006 227 34.4 30.8 38.0 
2007-2010 279 42.3 38.5 46.1 
Age Groups 
<40 23 5.0 3.3 6.7 
40-49 82 12.4 9.9 14.9 
50-59 237 35.9 32.2 39.6 
60-69 217 32.9 29.3 36.5 
>=70 91 13.8 11.2 16.4 
Parity(n=351) 
nulliparous 171 48.7 43.5 54.0 
Low Parity 21 6.0 3.5 8.5 
High Parity 159 45.3 40.1 50.5 
Employment(n=418) 
Employed 48 11.5 8.4 14.6 
Housewife 370 88.5 85.4 91.6 
Basis of Diagnosis 
Death Certificate Only 30 4.5 3.0 6.1 
Histology of Primary 614 93.0 91.1 95.0 
Cancer 
Topography 
Other 16 2.4 1.2 3.6 
Corpus Uteri Cancer 599 90.9 88.7 93.1 
NOS Cancer 60 9.1 6.9 11.3 
Tumor Grades 
Well Diff 94 14.2 11.6 16.9 
Mod Diff 300 45.5 41.6 49.3 
Poorly and Anaplastic 110 16.7 13.8 19.5 
Unspecified 156 23.6 20.4 26.9 
Tumor Stage(n=560) 
Localized 334 59.6 55.6 63.7 
Regional 19 3.4 1.9 4.9 
Distant 72 12.9 10.1 15.6 
Un staged 135 24.1 20.6 27.7 
Adenocarcinoma 447 68.1 64.6 71.7 
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Cancer 
Histology(n=656) 
Other carcinoma 78 11.9 9.4 14.4 
Sarcoma 72 11.0 8.6 13.4 
Other, unspecified malignant 
neoplasm 
59 9.0 6.8 11.2 
Treatment(n=516) 
No Treatment Given 120 23.3 19.6 26.9 
Surgery alone 246 47.7 43.4 52.0 
Surgery + adj RT 98 19.0 15.6 22.4 
Surgery + adj RT and or adj CT 52 10.1 7.5 12.7 
 
Table 8 shows the age specific incidence rate of uterine cancer. Descriptively, the age 
specific rate peaked at 22 per 100,000 and 95% CI (19.28-25.16) in the age group of 60-
69 years while the age specific rate was lower in subsequent age groups.   
Table8: Age-Specific Incidence Rate (per 100,000) of 660 Uterine Cancer diagnosed 
in Gharbiah Population, 1999-2010. 
Age at Diagnosis  Number of 
Cases 
Age Specific Incidence 
Rate 
/100,000 
95% Confidence Interval 
Lower Limit Upper Limit 
<40 33 0.19 0.13 0.26 
40-49 82 2.94 2.35 3.63 
50-59 237 12.52 11.00 14.19 
60-69 217 22.07 19.28 25.16 
>=70 91 16.65 13.49 20.34 
Total 660 2.78 2.58 3.00 
 
  
  
 
34 
 
The crude incidence rate of uterine cancer in Gharbiah province over the period of 1999 
through 2002 was 1.95 per 100,000 and 95% CI (1.6-2.3) and for the period of 2003 
through 2006 it was 2.9 per 100,000 and 95% CI (2.5-3.2). By 2007 to 2010 the crude 
rate had increased to 3.5 per 100,000 and 95% CI (3.1-3.9). The crude rate was higher in 
(2003-2006) and (2007-2010) compared to (1999-2002). The crude rate of uterine cancer 
in the period of 2007 to 2010 was 1.8 times the rate in the period of 1999 to 2002. Table 
9, shows uterine cancer crude rate and the increment in the rate ratio over the time with 
the significant 95% CI. 
Table 9: The crude rate of uterine cancer in Gharbiah province for pre and 
postmenopausal women with rate ratio (total n= 660) 1999-2010. 
Status 1999-2002 (ref) 2003-2006 2007-2010  
  CR 95% CI CR 95% CI CRR 95% CI CR 95% CI CRR 95% CI 
Pre-menopausal 0.44 0.3-0.6 0.5 0.4-0.7 1.2 0.74-1.95 0.7 0.52-0.93 1.6 1.04-2.57 
Post-menopause 10.87 8.96-12.78 16.7 14.37-19.12 1.5 1.23-1.95 20.2 17.55-22.77 1.9 1.49-2.31 
Total 1.95 1.64-2.25 2.9 2.50-3.24 1.5 1.20-1.81 3.5 3.11-3.94 1.8 1.49-2.21 
CR: Crude Rate 
CRR: Crude Rate Ratio 
Corpus uteri cancer comprises the majority of uterine cancers in both pre- and post-
menopausal women with proportions of 83% and 93%, respectively (Table 10). However, 
the NOS cancer has a higher proportion in pre-menopausal women (17%) than (7%) in 
post-menopausal women (p<0 .001).  
Carcinomas were the most common type in pre and post-menopausal women, 61% and 
84%, respectively. The tumor grades have significant association with the menopausal 
status (p< .001). About 10% and 15% of pre and postmenopausal respectively were well-
differentiated tumor grade. Moderately differentiated tumor comprised 38% of 
premenopausal and 47% of postmenopausal patients. Unspecified tumor grade had the 
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highest percentage of premenopausal women (41%) whereas only 20% of 
postmenopausal women had unspecified tumor grade. Poorly and anaplastic tumor grade 
comprised 11% and 18% of pre and postmenopausal patients respectively.  
Although, the nulliparity was relatively high in both premenopausal and post-menopausal 
(52% and 48%, respectively), the levels of the parity did not show a significant difference 
by menopausal status (p=0 .35). Moreover, treatment, residential status and employment 
status did not have any significant association with the menopausal status (Table 10). 
Table 10: The association of clinical characteristics and Menopausal Status of the 
Uterine Cancer Cases (n=660) Gharbiah Province 2010. 
  Menopause Status  Pearson 
/Exact Chi 
Square 
Pre  Post Pre  Post 
N N Col % Col % 
Cancer Site  Missing 0 1 
  
<.001 
Corpus Uteri Cancer 95 504 83% 93%  
NOS Cancer 20 40 17% 7% 
 
Basis of 
Diagnosis 
Death Certificate Only 10 20 9% 4% 0.04 
Histology of Primary 101 513 88% 94%  
Other 4 12 3% 2%  
Histology  Missing  2 2     <.001 
Adenocarcinoma 57 390 50% 72% 
 
Other carcinoma 12 66 11% 12%  
Sarcoma 23 49 20% 9% 
 
Employment  Missing 38 204     0.04 
Employed 14 34 18% 10%  
Housewife 63 307 82% 90%  
Parity  Missing 52 257     0.54 
Nulliparous 33 138 52% 48%  
Low Parity 5 16 8% 6% 
 
High Parity 25 134 40% 47% 
 
Residential 
Status 
Urban 60 295 52% 54% 0.70 
Rural 55 250 48% 46% 
 
stage  Missing  14 86     0.98 
Localized  62 272 61% 59%  
Regional  3 16 3% 4%  
Distant  13 59 13% 13%  
Unstaged  23 112 23% 24%  
Tumor Grade  Well Diff  11 83 10% 15% <.001 
Mod Diff  44 256 38% 47% 
 
Poorly and Anaplastic  13 97 11% 18% 
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Unspecified  47 109 41% 20% 
 
Treatment   Missing 32 112     0.04 
No Treatment Given  14 106 17% 25%   
Surgery alone  37 209 45% 48%   
Surgery + adj RT  17 81 21% 19%   
Surgery + adj RT and or 
adj CT 
15 37 18% 9%   
 
Table 11 displays the association of histology with different clinical characteristics of 
uterine cancer. About half of the carcinoma patients were diagnosed with moderate tumor 
grade. Histological types of cancer have significant differences across the levels of tumor 
grades, 59% of adenocarcinoma were moderately differentiated, 53% of other carcinoma 
were unspecified tumor grade and 32% of sarcomas were diagnosed with poor and 
anaplastic tumor grade (p <0.001). All sarcomas (100%) were diagnosed as corpus uteri 
whereas 75% of other and unspecified malignancies were diagnosed as NOS uterine 
cancers. The highest proportions of all histological types that were treated with surgery 
only were sarcoma (63%) followed by adenocarcinoma (48%). Histological types of 
cancer had significant influence over the treatment options that were given (p <0.001).   
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Table 11: The association of histology types of cancer and different clinical 
characteristics, (n=660) Gharbiah, 2010. 
  
Histology Types 
Adeno-
carcinoma 
Other 
carcinoma 
Sarcoma 
Other and 
unspecified 
malignant 
neoplasm 
P 
N N N N 
% % % % 
Tumor 
Grade  
Well Diff 
83 2 9 0 
<.0001 
19 3 13 0 
Mod Diff 
262 14 22 1 
59 18 31 2 
Poorly and 
Anaplastic 
65 21 23 0 
15 27 32 0 
Unspecified 
37 41 18 58 
  
8 53 25 98 
Cancer Site  
Corpus Uteri 
Cancer 
440 69 72 15 <.0001 
98 90 100 25   
NOS Cancer 
7 8 0 44   
2 10 0 75   
Stage  
Missing 72 9 17 2 
<.001 
Localized  
245 42 35 10 
65 61 64 18 
Regional  
13 2 3 1 
3 3 5 2 
Distant  
37 13 14 7 
10 19 25 12 
Unstaged  
80 12 3 39 
21 17 5 68 
Treatment 
Missing 102 25 13 22 
<.0001 
No Treatment 
Given 
74 13 6 26 
21 25 10 70 
Surgery alone 
166 23 37 7 
48 43 63 19 
Surgery + adj RT 
68 12 12 0 
20 23 20 0 
Surgery + adj RT 
and or adj CT 
37 5 4 4 
11 9 7 11 
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Discussion: 
This study revealed three findings. First, the uterine cancer ASR in this population was 
relatively low during the entire study period of 1999-2010, however the crude and ASRs 
increased significantly by 2010. Second, the peak age-specific incidence rate of uterine 
cancer was in the age group of 60-69 years. Third, adenocarcinoma and other carcinomas 
comprised about 80% of all uterine cancers in this population.  
There are a limited number of studies examining ASR of uterine cancer in Egypt. The 
first population-based study, included data from 1999-2001, in the monograph of the 
Middle East Cancer Consortium (MECC). 121 The MECC report included the period 
1999-2001 and showed an ASR of 3.5 per 100,000 in this population in Egypt compared 
to ASR of 5.8 per 100,000 for Jordan, ASR of 8.7 per 100,000 for Israeli Arabs, ASR of 
13.8 per 100,000 for Israeli Jews, ASR of 11.8 per 100,000 for Cyprus, and ASR of 17.6 
per 100,000 for SEER, USA. 121. A more recent study showed a crude incidence rate of 
uterine cancer of 1.91 per 100,000 for the same population for the period of 1999 to 
2002. 122 However, based on the Cancer Incidence in Five Continents Vol. X, 29 other 
Arab countries have higher ASRs than the Egyptian rates. For example, Saudi Arabia, 
Kuwait and Qatar had ASRs of 4.7, 6.7, and 8.4 per 100,000, for the 3 countries, 
respectively. 29 Rates reported from developed countries in Europe or North America 
were significantly higher than the Egyptian rates (19.5, 17.0, and 13.9 per 100,000 for the 
US, France, and the U.K., respectively. 113 In addition, the world uterine cancer ASR as 
reported in Globocan 2012 was 8.2 per 100,000. 113 Therefore, the results of this study 
clearly show that the Egyptian ASR of uterine cancer is considered one of the lowest 
uterine cancer incidence rates, globally.  
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Regarding the trend of increasing uterine cancer crude rates in Egypt, other studies 
showed increasing trends of uterine cancer incidence in some European countries. For 
example, the incidence of uterine cancer increased significantly in the period of 1988 to 
2008 in Norway, Ireland, the United Kingdom, and the Netherlands. 133 Some Asian 
countries also showed continuous increase in uterine cancer incidence rates. For example, 
five out of 6 population-based cancer registries in India showed an increase in uterine 
cancer trend over the period of 1982 to 2003. 134 In addition, the increment in the uterine 
cancer trend was noticed also in Japan over the period of 1983 to 2005. 135 In contrast, the 
rates declined in Austria, Sweden and Germany. 133 In the U.S., the trend showed 
declining rates for 3 decades until the 1990, stability in the 1900s, then slight increase 
after 2007.136 
The significant variations in ASRs across different countries could be explained by the 
variation in risk factors for uterine cancer or health care factors influencing the diagnosis 
of the disease. 130 The increasing rates in Gharbiah province of Egypt over the study 
period could be related to both risk factors and health systems factors. It is unlikely that 
an improvement in the population-based registries has been a factor, since these have 
maintained consistently high standards verified by peer review.137,138 
Early age of menarche, late age of menopause, nulliparity, obesity, and diabetes mellitus 
are well-documented risk factors for uterine cancer in different countries.   
Early age of menarche and late age of menopause are two risk factors related to increased 
risk for uterine cancer. 38,44,46,50,75 Average age of menarche in high and low SES girls in 
Egypt was reported in 1978 as 12.59 years and 13.89 years, for the two groups, 
respectively. 139. A more recent study showed that the mean age at menarche in Egypt 
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declined to 12.49 years in the period of 2012-2013. 140 Age of menopause has increased 
in Egypt over time. In 1986, a study from the Sharkia province in Egypt showed an 
average age of menopause of 45.2 years. 141 and another study from Alexandria, Egypt 
showed an average of menopause of 45.8 years. 142 Studies from the rural province of 
Menoufia showed a lower average age of menopause of 43.1 years. 143 More recent 
studies showed a higher average of menopause of 46.7 and 50.84 in Alexandria and 
Assiut respectively.144-146 
Regarding the relationship between parity and uterine cancer, low parity has been 
considered a risk factor while high parity was considered a protective factor for the 
disease 147,148 The fertility rate among Egyptian women (15-49 years) was 3.5 births per 
woman in 2014. 149 Although, the fertility rate declined from 5.3 to 3.5 births per woman 
during the period of 1980 to 2014, the rate still is higher than that of developed countries. 
For example, the fertility rates in the U.S., France, and the U.K. were reported as 1.9, 2.0 
and 1.9 respectively in 2011-2015. 150 There were no significant association of parity 
levels and menopausal status of Gharbiah women. Therefore, both groups of women have 
maintain the same level of parity.  
Obesity is considered an important risk factor for endometrial cancer for both pre- and 
postmenopausal women. 49,56,88,104,151,152 About 39% of the risk for endometrial cancer can 
be attributed to overweight and obesity. 153 Egypt has been considered one of the 
countries with the highest overweight and obesity rates. 154 The Egyptian Demographic 
and Health Survey (EDHS) showed an increase in obesity from 40.85 to 48.1% during 
the period of 2000 through 2014. 149,155-157 According to the WHO estimate for 2010-
2014, obesity (BMI ≥ 30) prevalence among Egyptian females aged 18+ was 37.5% 
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(95% CI 30.5-44.9). 154 A hospital-based study from Alexandria, Egypt showed 
abdominal obesity as a significant risk factor for endometrial cancer (OR= 13.58, 95% CI 
(4.0-46.6). 158 Moreover, diabetes mellitus is a well-known risk factor. 159-161 The 
prevalence of diabetes mellitus in Egyptian women increased from 8% in 1980 to 18.2% 
in 2014. 162 Therefore, the increase in some uterine risk factors over the last decades 
could explain the increasing incidence of uterine cancer in our study.  
Egypt is one of the middle-income countries that have been undergoing epidemiologic 
and nutritional transitions. 163-165 For example, the prevalence of overweight and obesity 
were 28.2% and 7.6%, respectively, among Egyptian schoolgirls of mean age of 13.2 
during the period of 2006-2010. 152 If increasing trends of overweight and obesity 
continue among Egyptian women, endometrial cancer might be expected to continue to 
increase in the future.  
Although, variations in risk factors may explain differences in incidence of uterine cancer 
between populations, protective factors may also play a role in variation in rates between 
countries. For instance, smoking is another risk factor that has been associated with low 
rates of uterine cancer in postmenopausal women. 84,166,167 However, it should be noted 
that smoking rate among Egyptian women is extremely low (0.5%), compared to the 
male population (37.7%).168,169 However, these studies did not address the possibility of 
exposure of women to passive smoking.  
Oral contraceptive pills and injectable contraceptive methods are considered protective 
against endometrial cancer. 170,171 The estimated prevalence of using birth control pills of 
Egyptian women of reproductive age (15-49 years) was 16.6 % in 1980 and declined to 
9.5% in 2000 then increased again to 16% in 2014. 172 However, there has been a constant 
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increase in the use of injectable contraceptive methods from 0.1% in 1988 to 8.5% in 
2014. 149 These rates of usage are quite low compared to rates in developed countries that 
reach 40%.172. In addition, the increases in physical activity were found protective against 
uterine cancer 173-175. About 57% of women living in rural areas in our study region were 
engaged in daily activities and work in extensive farm-related physical work, which 
demanded a considerable amount of physical activity. 131 Moreover, the different 
exposure to environmental factors may affect uterine cancer incidence. For instance, 
exposure to xenoestrogens as a component of environmental estrogen may have an 
influence on increasing uterine cancer rates. 122. 
About 36% of the patients included in our registry were in the age group 50-59 years. 
And the age specific rate was the highest (22.07 per 100,000) among the age group of 60 
to 69 years. This result does not differ from uterine cancer data worldwide. 3,176 The 
decrease in the hormonal imbalance for both exogenous and endogenous hormones may 
explain the decline in the uterine cancer incidence among elderly women. 177 Use of 
hormonal replacement therapy (HRT) by menopausal women is linked to increasing rates 
of uterine cancer. 147,178,179 However, HRT is rarely used in Egypt and is not known to 
most women in Egypt. 145,180.  
Egypt has a wide-spread system of primary health care and access to medical care in 
primary care, hospitals, and private clinics is not a major barrier to receiving medical 
care. 131 Also, availability of resources for imaging and pathologic diagnosis of cancer 
have improved significantly in Egypt. 137,138 Whether these resources are available by 
physicians in the diagnosis of uterine cancer is unknown and if resources are under-
utilized, that could result in under-diagnosis of uterine cancer in this population.    
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Regarding the histologic types of uterine cancer, the majority of all histologic types of 
uterine cancer in this study were carcinoma and the adenocarcinomas. The results of this 
study are in agreement with the classic presentation of adenocarcinoma among uterine 
cancer patients elsewhere. For example, the adenocarcinoma comprises over 90% of all 
uterine cancer in the US. 181 However, in Tunisia, which is one of the North African 
countries, the adenocarcinoma was about 63% of uterine cancer patients. 182   
Most of uterine cancers in this study were among postmenopausal women. This finding is 
consistent with studies from the U.S. where more than 90% of uterine cancer patients are 
postmenopausal. 3  
The study has several strengths. The study builds on a track record of a reliable 
population-based cancer registry with validated data. The relatively long period of the 
study (12 years) adds to the strengths of the study. The coverage of medical care and 
accessibility to health care facilities in Egypt minimize the chance of missed cases that 
had no access to medical care. Whether or not physicians histopathologically confirm the 
diagnosis of all uterine cancers in this population could be a factor in under-estimating 
uterine cancer in this population. Also, because of the low incidence of uterine cancer in 
this population, the relatively-small sample size of this study might be a limitation. 
In summary, while the uterine cancer incidence rate is low, but increasing over time in 
Gharbiah province of Egypt compared to other countries, the postmenopausal Egyptian 
women comprised the vast majority of uterine cancer as in other countries. Future studies 
should focus on elucidating the impact of epidemiologic, demographic, and nutritional 
transitions on the future of uterine cancer in this population. Future studies should also 
investigate if uterine cancer is under-estimated in this population, although this is 
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unlikely due to population-wide accessibility to medical care in Egypt. Finally, 
researchers should explore if the increasing environmental pollution and environmental 
estrogens may have an impact on regional distribution of the disease in rural and urban 
regions of this population.   
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Chapter 3:  
Clinical and Demographic Characteristics of Uterine Cancer by Rural-Urban 
Residence in Gharbiah, Egypt (1999-2010) 
Background 
Uterine cancer is among the top-ranking cancers affecting women worldwide. 113 There 
are wide international variations in the disease incidence and by rural-urban place of 
residence within countries.183-186 
Incidence rates of cancer, including those for uterine cancer, tend to be higher in urban 
compared to rural populations. 183,187,188 However, the gap between rural and urban areas 
in cancer incidence has decreased over time, especially in the developed countries. 189 
Limited number of studies exist on uterine cancer distribution by rural and urban areas in 
developing countries.  
Hormonal exposures implicated in uterine cancer etiology and access to health care in 
disease management varies between rural and urban areas, globally. 184-186,190-193 
According to a previous study from the Gharbiah Population-based Cancer Registry 
(GPCR) for 1999-2002, the incidence of gynecological cancers (ovary, uterine and 
cervical) was higher in urban compared to rural areas. 122 Uterine cancer showed highest 
urban–rural incidence rate ratio among the 3 gynecologic cancers (IRR = 6.07, 95% CI = 
4.17, 8.85) whereas the ovarian and cervical cancers had 2.57 and 3.11 respectively. 
Urban areas had higher incidence rates and older age at diagnosis of uterine cancer 
compared to rural areas and a relatively low rate of uterine cancer in this population 
compared to the global rates of the disease. 122,194  
  
 
46 
The Gharbiah province comprises about 5.5% of Egyptian the population and about 70% 
of the population lives in rural areas. 131 With the availability of a larger dataset from the 
registry for the period 1999-2010, and improvement in medical and diagnostic facilities 
in the region137, this study aimed at examining the rural-urban difference in uterine cancer 
in Gharbiah.  
Methods:  
Data included in this study was obtained by abstracting clinical and demographic 
information of all 660 patients who resided in the Gharbiah province and diagnosed with 
uterine cancer during the period of 1999-2010. The Gharbiah Population-based Cancer 
Registry of (GPCR) province in Egypt was the source of information in this study. The 
GPCR is a population based cancer registry established based on the Middle East Cancer 
Consortium (MECC) in 1999. The Cancer Society in Tanta, the capital city of Gharbiah, 
hosts GPCR. Highly trained staff collected the data actively from across the entire region. 
Data were obtained by abstracting clinical and demographic information from the GPCR 
for all 660 patients who resided in the Gharbiah province and were diagnosed with 
uterine cancer during the period of 1999-2010. Data of all Gharbiah province patients 
diagnosed with cancer and Gharbiah patients seeking medical advice outside the region 
were included in the registry.        
Uterine cancers included in the registries were classified based on the international code 
of disease classification (ICD-O-3). 195 Corpus uteri included codes C54.0 – C54.9 and 
uterus not otherwise specified (NOS) cancer included code C55.9.  
Rural-urban residence was based on the classification of the Egyptian Central Agency for 
Public Mobilization and Statistics (CAPMAS). The Gharbiah province consists of the 
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following 8 districts: Tanta, Mehalla, Kafr Zayat, Zefta, Samanood, Santa, Kotoor and 
Basyoon. Each district has a capital city and surrounding villages. The population of the 
capital cities of each district was considered urban residents while the population of the 
remaining areas of each district was considered rural residents. 131 Residence was 
considered rural or urban based on the permanent residence address of patients.  
The total population of women in Gharbiah province was 1,977,324 in 2006 (last 
published census). 131 About 70% of residents were rural and 30% were urban. Data from 
the Egyptian census of 2006 was used for calculating incidence rates in this study. 131  
Medical care in the province is provided through a large network of public and private 
clinics and hospitals including 257 primary health care units, 57 integrated hospitals and 
2 central hospitals in rural areas and 88 urban hospitals. 
The incidence rate of uterine cancer was calculated for rural, urban, and the total 
population. The world standard population of WHO 2000 was used to calculate the age-
standardized rate (ASR). 29 The rate ratio was calculated to compare the rates in rural and 
urban areas and to examine the incidence trend over time. The study period was divided 
in to 3 periods; 1999-2002, 2003-2006 and 2007-2010. The first period was used as a 
reference period in calculating rate ratio; the rate in the last period was compared to 
second period. 
The crude incidence rates (IR) were calculated by dividing the total number of uterine 
cancers (E) by the total number of women at risk in the same population per 100,000. The 
formula of CI= IR±1.96 × IR/√E was utilized to calculate the 95% Confidence Interval 
(CI). The rate ratio of uterine cancer in urban areas versus rural areas was calculated by 
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dividing the incidence rate in urban areas (IR1) by the incidence rate in rural areas (IR2). 
The CI of Rate Ratio = exp [In (IR1/IR2)] ± 1.96 × √ (1/E1 + 1/E2). The Chi-square test 
was used to compare categorical variables. A two-sided p-value ≤0.05 was considered 
statistically significant. Statistical analysis was conducted using SAS version 9.4 (SAS 
Institute Inc, Cary,NC).       
The study was approved by the IRB committees of the University of Nebraska Medical 
Center and the Gharbiah Cancer Society in Egypt.  
Results:  
Slightly more than half the patients (54%) resided in urban areas while 46% of patients 
resided in rural areas. There were no significant differences between patients residing in 
rural and urban areas with respect to following menopausal status [rural premenopausal 
(18%) vs. urban premenopausal (17%)] and parity [rural nulliparous (48%) vs. urban 
(49%)].  However, occupation was significantly different in rural vs. urban women; only 
4% of rural women were employed compared to 19% of urban women (p< 0.001).  
Tumor morphology had a significant association with the residential status. 
Adenocarcinoma was the most common type in both rural and urban patients, 66% and 
70%, respectively. Sarcoma was found equally (11%) in each of the urban and rural 
patient groups. About 8% of urban uterine cancers were classified as “other carcinoma” 
whereas double of that proportion (16%) was found in rural areas. The majority of uterine 
cancer cases were diagnosed as “localized” in both urban (56%) and rural (64%) areas. 
About 48% of patients with treatment data had surgery alone, in both rural and urban. 
Tumor stages, grades, and treatment did not show any significant association with place 
of residence (Table12).    
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Table 12: Clinical and demographic characteristics of 660 uterine cancer patients in 
Gharbiah, Egypt during the period of 1999-2010 by urban and rural status  
 
Characteristic 
  
Place of Residence 
P value 
Rural Urban 
N (%) N (%) 
Menopausal Status 
Pre-Menopause 55 (18%) 60 (17%) 0.70 
Post-Menopause 250 (82%) 295 (83%) 
 
Occupation Status (n=418) 
Employed 9 (4%) 39 (19%) <.001 
Housewife 201 (96%) 169 (81%) 
 
 Parity(n=351) 
Nulliparous 87 (48%) 84 (49%) 0.86 
Low Parity 12 (7%) 9 (5%)  
High Parity 81 (45%) 78 (46%)  
Cancer Site 
Corpus Uteri Cancer 284 (93%) 315 (89%) 0.07 
NOS Cancer 21 (7%) 39 (11%) 
 
Tumor Histology 
Adenocarcinoma 198 (66%) 249 (70%) 0.01 
Other carcinoma 49 (16%) 29 (8%) 
 
Sarcoma 32 (11%) 40 (11%) 
 
Other and unspecified 23 (8%) 36 (10%) 
 
Tumor Stage(n=560) 
Localized 166 (64%) 168 (56%) 0.18 
Regional 6 (2%) 13 (4%) 
 
Distant 33 (13%) 39 (13%) 
 
Unstaged 55 (21%) 80 (27%) 
 
Tumor Grade 
Well differentiated 39 (13%) 55 (16%) 
 
Moderately differentiated 136 (45%) 164 (46%) 0.07 
Poorly differentiated 63 (21%) 47 (13%) 
 
Undifferentiated anaplastic 67 (22%) 89 (25%) 
 
Treatment(n=516) 
No Treatment Given 59 (23%) 61 (24%) 0.99 
Surgery alone 125 (48%) 121 (48%) 
 
Surgery + adj RT* 50 (19%) 48 (19%) 
 
Surgery + adj RT and or adj 
CT** 27 (10%) 25 (10%) 
 
* Radiotherapy  
** Chemotherapy 
 
Urban areas had the highest age-specific rates for all age groups (Table 13). However, 
rural and urban patients had the same pattern of increasing rates with the increase of 
women’s age up to the age group of 60-69.  
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Table 13: Age specific rates of 660 uterine cancer patients resided in rural and 
urban Gharbiah, Egypt 1999-2010 
AGE Rural  Urban 
AGE Group 
No. of 
Cases 
Age Specific 
Rate/100,000 95% CI No. of Cases 
Age Specific 
Rate/100,000 95% CI 
<40 17 0.14 (0.08-0.21) 16 0.32 (0.19-0.50) 
40-49 38 2.05 (1.47-2.78) 44 4.71 (3.47-6.26) 
50-59 108 8.90 (7.34-10.70) 129 18.98 (15.92-22.48) 
60-69 105 16.03 (13.18-19.32) 112 34.14 (28.25-40.92) 
>=70 37 9.65 (6.90-13.15) 54 33.12 (25.14-42.87) 
Total 305 1.84 (1.64-2.06) 355 4.96 (4.47-5.50) 
 
The crude rates of uterine cancer were consistently higher in urban than rural areas, 
during the period of 1999 to 2010. The overall crude incidence rate of uterine cancer 
during the period 1999-2002 was 1.95 per 100,000 with 95% CI of 1.64-2.25. Rural 
crude incidence rate was 0.78 per 100,000 while the rate was 4.65 per 100,000 in urban 
areas. The gap between the 2 crude incidence rates of rural and urban areas declined in 
the last 2 periods (2003-2006 and 2007-2010).  
 The rural ASR was 2.8 (95% CI: 2.48-3.13) compared to 6.9 (95% CI: 6.13-7.66) per 
100,000 in urban areas.  The rate ratio showed that the incidence rate of uterine cancer in 
urban areas was 2.46 times the rate in rural areas (Table 14).  
Table 14: Crude and adjusted incidence rates and rate ratio of uterine cancer in 
rural and urban of Gharbiah, Egypt 1999-2010, (N=660) 
  N  CR 95% CI RR 95% CI ASR  95% CI RR 95% CI 
Rural  305 1.84 (1.64-2.06) 1.00  2.80 (2.48-3.13) 1.00  
Urban  355 4.96 (4.47-5.50) 2.70 (2.31-3.14) 6.90 (6.13-7.66) 2.46 (2.10-2.88) 
N: Number of Cases 
CR: Crude Rate per 100,000 population 
ASR: Age standardized Rate per 100,000 population based on world standards population (WHO 2000). 
RR: Rate Ratio (Rural residence was used as a reference) 
 
Table 15 shows the crude rate of uterine cancer over time for each of the geographic 
areas of Gharbiah. The crude rate increased over time for both rural and urban areas. The 
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rate ratio between time periods in rural areas, considering 1999-2002 as a reference 
period, steadily and significantly increased over time as the crude rate ratio was 2.7 with 
95% CI of 1.94-3.89 for 2003-2006 and 3.4 with 95% CI 2.38-4.71 for 2007- 2010, in 
comparison with reference time period. Although the crude rate was always higher in 
urban areas, the rate ratio did not show any significant increase over time. Figure 2 shows 
the steady increase of crude rates in both rural and urban areas all over the time 
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Table 15: Crude incidence rate of 660 uterine cancers in rural and urban 
Gharbiah over the period of 1999 to 2010 
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Figure 2: Time trend of uterine cancer crude rate in Gharbiah province, 1999-2010 
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Discussion: 
This study revealed the following interesting observations. First, there were no 
differences in most clinical and demographic characteristics between patients from rural 
and urban areas. Second, age-specific rates showed similar patterns of increase with 
aging for patients from both rural and urban areas.  Third, uterine cancer incidence rate 
was significantly higher in urban areas compared to rural areas. Fourth, uterine cancer 
incidence rates increased from 1999 to 2010 in rural areas but not in urban areas.   
Regarding the lack of difference in clinical and demographic characteristics between 
patients from rural and urban areas and increasing uterine cancer rates with aging, it is 
important to note that accessibility and affordability of health care in this population is 
not an impediment to receiving appropriate cancer management.  Health care facilities 
(health units, primary care centers, private clinics, and private and public hospitals) are 
available and accessible to both rural and urban populations. For example, there are more 
than 300 primary health care, integrated hospitals and central hospitals distributed 
throughout the rural areas. In addition, the distance between remote rural sites of the 
province and respective capital cities of the districts is no more than 20 kilometers. Also, 
various methods of transportation are available and affordable if special diagnostic or 
treatment regimens are needed. Increasing the accessibility to health care has reduced 
mortality rates in the U.S. by providing early diagnosis and specific treatment for uterine 
cancer. 196 Furthermore, the impact of improving diagnostic and management facilities in 
Gharbiah showed a significant impact on diagnostic methods of cancer patients included 
in the Gharbiah registry in both areas. 137,138   
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A systematic review of the literature from 1992 to 2012 that included a total of 366,299 
uterine cancer patients in the U.S., revealed an association between socioeconomic status 
(SES), incidence, stage at diagnosis, and survival rates. 197 Patients with low SES 
presented more frequently with advanced-stage of uterine cancer that may attributed to 
the low accessibility of health care. 198-200 Disparities in access to health care may explain 
the relationship between SES and disparities in incidence rates and stages of diagnosis of 
uterine cancer in the U.S. However, health care accessibility and affordability were not 
barriers to receiving care in rural and urban areas of our study population in Egypt. This 
may explain why tumor grades and stages at diagnosis were not associated with place of 
residence of patients in our study population in Egypt. 
The pattern and increment of age-specific rates among rural and urban women age in this 
population was consistent with global trends for uterine cancer in both developed and 
developing countries, as reported in Cancer Incidence in Five Continents.29 
The higher incidence of uterine cancer in urban than rural areas was observed in previous 
study. 122 It was conducted in the same population on a shorter time period (1999-2001) 
and it showed crude incidence rates of 0.74 and 4.52 per 100,000 in rural and urban areas 
compared to 1.84 and 4.96 per 100,000 in rural and urban areas, respectively. 122 The 
ratio of urban to rural rates decreased from 6.07 in the first study to 2.70 in the current 
study. The changes in incidence rate ratios over the study period emphasize the 
increasing rate in rural areas and stable rates in urban areas, which was reflected on 
narrowing the gap between rural and urban rates. While the rural ASR in this study (2.8 
per 100,000) is significantly low compared to the urban ASR (6.9 per 100,000) that is 
relatively close to the global average ASR of uterine cancer. 109   
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The significant difference between rural and urban rates as well as increasing rural rates 
revealed in this study might be a reflection of changes in risk factors of uterine cancer in 
this population over time. Examples of these risk factors include parity, obesity, early age 
of menarche, contraceptives, and physical activity.  
Parity has been inversely associated with uterine cancer in several studies from various 
countries. 31,37,148,201 In Egypt, higher fertility rates have been reported in rural compared 
to urban areas, including our study population in Gharbiah. It is important to note that 
fertility rates have declined in rural areas of Gharbiah from 4.6 per 1000 women in 1988 
to 3.6 per 1000 women in 2014 and from 3.8 per 1000 women in 1988 to 3.0 per 1000 
women in 2014 in urban areas.149 
Obesity is a strong risk factor for uterine cancer. 49,56,158,202 The obesity and overweight 
data that was collected by World Health Organization showed that Egypt has high obesity 
rate compared to many countries worldwide. 154 During the 1990s, average BMI was 
higher among urban (29.8 kg/m2) compared to rural women (26.8 kg/m2).  203 This gap 
declined over the time. The average BMI were 31.1 kg/m2 in urban areas and 31.0 kg/m2 
in rural women in 2014. Therefore, the risk factor of uterine cancer in rural women has 
increased compared to urban areas. 
Early age of menarche has been identified as one of the factors that have lifetime risk for 
uterine cancer. 15 In Egypt, the urban girls tend to have an earlier age of menarche 
compared to those in rural areas in 1980s.  139 In addition, age at first marriage in rural 
areas is younger than in urban areas. The median age at first marriage was 20 and 22.4 
years in rural and urban women in Egypt, respectively. 149, Therefore, there was about 
10% of young women in the age group of 15 to 19, who had at least one pregnancy. 149 
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Therefore, urban women were exposed to high risk of uterine cancer for a longer time 
during their lifetime compared to rural women.  
Oral contraceptive rates were low and with no clear difference among rural and urban 
women of Egypt. 149 However, previous studies suggested that higher rates of uterine 
cancer in urban than rural areas might be related to higher xenoestrogenic exposures in 
urban than rural areas. 122 The stable incidence rate in urban areas compared to rates in 
rural areas might be related to nutritional and epidemiologic transition. 204 The 
urbanization of rural areas, dietary factors and food sources and epigenetic factors205-207 
may lead to weaken the estrogenic compounds in both urban and rural population.208-210 
Physical activity plays a significant role in risk reduction of uterine cancer by lowering 
the level of serum estradiol, which may help in reduction weight gain.  94,174,175,211 
Physical activity of rural women in Egypt is significantly higher than the activity of urban 
women. Occupational activities in farming, livestock breeding and less technological 
household environment translate to higher level of activity in rural areas compared to 
urban areas. 131  
This study has several strengths. The study period spans over 12 years. The population-
based nature of the study and the validated quality of the data add to the strength. 
Comparing the results with previous research from the same region highlights the impacts 
of the changes in lifestyle, demographic, and environmental factors on the epidemiology 
of uterine cancer in this population.  
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However, the study has several limitations.  The registry-based nature of the study did not 
provide information about lifestyle and risk factors. The low number of uterine cancer 
patients in this population was another limitation.  
In summary, this study revealed the increasing rates of uterine cancer in rural areas and 
stable but much higher rates in urban areas in Gharbiah, Egypt.  Future studies should 
elucidate the etiology of uterine cancer in both urban and rural populations in Gharbiah 
and other regions in Egypt. The studies should also quantify the impact of nutritional and 
epidemiologic transitions in this population. While no significant difference existed in 
stage of presentation or type of treatment, further studies should examine the diagnostic 
methods, treatment outcomes, and uterine cancer-specific mortality in rural and urban 
regions. 
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Chapter 4:  
Impact of Hysterectomy on Uterine Cancer Incidence Rates in Egypt 
Background: 
Uterine cancer is one of the common cancers affecting women worldwide. 109 However, 
there are significant variations in the incidence globally with highest rates in North 
America (19.1 per 100,000) and lowest rates in Africa (3.5 per 100,000).194 
The age-standardized incidence rate of uterine cancer in Egypt was reported in 2012 as 
3.8 per 100,000 compared to a global average incidence of 8.2 per 100,000. 194 Uterine 
cancer is ranked as the tenth most common women’s cancer in Egypt. Reports from the 
Middle East Cancer Consortium (MECC) showed that the incidence rate of uterine cancer 
in Egypt was the lowest (3.5 per 100,000) compared to rates from other MECC countries 
in the region: Jordan (5.8 per 100,000), Israeli Arabs (8.7 per 100,000), Cyprus (11.8 per 
100,000) and Israeli Jews (13.8 per 100,000).121 
In addition to the wide range of geographic variation in the uterine cancer incidence rate 
in the Middle East, underestimation of uterine cancer is suspected in Egypt due to the 
presumed frequent hysterectomy procedures in the country.149,212 
Surgical resection of the uterus (hysterectomy) is one of the main lines of surgical 
treatment of uterine cancer. There are also other medical indications for performing a 
hysterectomy. 213 These indications include uterine leiomyomas (fibroid), dysfunctional 
uterine bleeding, endometrial adenomyosis, genital prolapse, chronic pelvic pain, pelvic 
inflammatory disease, massive postpartum hemorrhages, endometrial hyperplasia and 
uterine cancers. 214 The majority of hysterectomies are performed for managing non-
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malignant conditions and fibroids are considered the most common indication for 
hysterectomy. 215 Non-malignant conditions that were treated by hysterectomy accounted 
for 88%, 81%, and 78% of all hysterectomies procedures in the US, 124 Germany125 and 
Sweden126, respectively.  
Hysterectomy is one of the most common gynecologic surgical procedures for women 
worldwide and has been reported in 2009 as the second most common surgery for women 
in the U.S. (479,814 hysterectomies/year). 216 The incidence rate of hysterectomy varies 
across the globe, with reporting rates of 510 per 100,000 in the US, 217 a much lower 
incidence rate in Europe as demonstrated by an incidence rate of 173 per 100,000 in 
Denmark. 218 Unfortunately, Egypt and most of developing countries have a scarcity of 
research in hysterectomy.  
Some studies have suggested that hysterectomy might be a factor in underestimating the 
observed incidence of uterine cancer. It has always been believed that white non-
Hispanic women have a significantly higher incidence of uterine cancer than the 
incidence in other racial groups in the U.S.  It is interesting to note that the overall age-
adjusted endometrial cancer rate increased 66.8% in all race groups after correcting for 
hysterectomy prevalence. 127 After adjusting for hysterectomy, Blacks had the highest 
increase in endometrial cancer incidence rate by 95.3%, followed by 65.1% for White 
non-Hispanics and 57.6% for Hispanics. These adjustments provided a better 
understanding of the actual incidence rates between the different ethnic groups 
considering the influence of different hysterectomy rates among them. 127 Therefore, 
adjustment for hysterectomy was an important factor in documenting the actual uterine 
cancer rate in the U.S. population. Other studies125, 128 supporting this finding, reported 
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that the hysterectomy correction has a different effect on the incidence rate of 
endometrial cancer in different geographical regions of the U.S. For example, the 
hysterectomy correction had a high impact on rates in Southern U.S. compared to other 
U.S. regions. 117  
Adjusting for hysterectomy had different levels of effect on the uterine cancer incidence 
rate depending on the prevalence of hysterectomy in different countries. For example, 
after adjusting for the prevalence of hysterectomy, uterine cancer incidence rates 
increased in England and Wales from 13.4 to 16.2 per 100,000, from 15.9 to 23.0 per 
100,000 in Germany and from 14.6 to 18.8 per 100,000 in Finland.219-221 
In Egypt, there are no clear data about the prevalence of hysterectomy and the indication 
of this surgery. However, there are clinical impressions about a frequent practice of 
hysterectomy in the country. Because of the documented low incidence of uterine cancer 
in Egypt and the presumed high rates of hysterectomy, this is the first study to quantify 
the impact of hysterectomy rate on the incidence rate of uterine cancer in Gharbiah 
province of Egypt.  
 Methods:  
The population of the study region: 
The Gharbiah province is located in the center of the Nile delta region of Egypt in a space 
area of 1,948 km2 and a population of approximately 4,011,320. The province is 
composed of eight districts: Tanta, Al-Maḥallah al-Kubrā, As-Sanṭah, Basyoun, Kafr az-
Zayyāt, Quṭūr, Samannūd, and Zefta. The two main districts that encompass the majority 
of the Gharbiah population and health care facilities are Tanta (TA) and Al-Mahallah Al-
kubra (MK). Approximately 50% of the population lives in TA and MK.  
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The hysterectomy dataset: 
The primary pathology labs that examine all uterine specimens in the province were 
included in this study. The main pathology labs in Tanta are located at the Tanta 
University Medical School, the Gharbiah Cancer Society (GCS), the Menshawy hospital 
and three other private labs. In MK and Kafr az-Zayyāt, there are three private labs that 
could receive and examine uterine specimens. Patients from the other 6 districts of 
Gharbiah come to these pathology labs if uterine specimens need histopathologic 
examination. Based on the Ministry of Health regulations in Egypt, uterine biopsy after 
every hysterectomy procedure must be sent to a pathology lab for histopathologic 
examination before treatment.  
All logbooks of the above-listed labs in 2013 and 2014 were reviewed. The review was 
limited to this period since records prior to 2013 were not available because of inadequate 
storage spaces in the labs. After identifying all uterine biopsies from the logbooks, 
pathology reports of each case were examined. In the Gharbiah city of Tanta, there were 
1055 hysterectomy specimens among 3072 benign uterine lesions. There were 306 
hysterectomy specimens identified from 1008 cases of benign uterine lesions in MK. 
Samples included in this study represented all patients from all districts of Gharbiah aged 
18-80 years.  
Variables abstracted from pathology reports included lab ID number, age, clinical 
presentation, type of surgery, date of the procedure, pathologic diagnosis, pathology lab 
and district referral surgeon. 
The incidence rate of uterine cancer for Gharbiah was calculated using the Gharbiah 
population-based Cancer Registry (GPCR) for uterine cancer cases included in the period 
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1999-2010 and the population data from the Central Agency for Public Mobilization and 
Statistics (CAPMAS) census. 131  
Data management and statistical analysis:  
The incidence rate (IR) of hysterectomy (E) was calculated for 2013 and 2014 in the 
Gharbiah region by dividing the number of newly-diagnosed cases of hysterectomy by 
the population of women in Gharbiah during the same time period. The 95% Confidence 
Interval (CI) was calculated using the following formula: CI= IR±1.96 × IR/√E.  
In order to adjust for the effect of hysterectomy on uterine cancer incidence rates, all 
women with hysterectomies (prevalent cases) were eliminated from the denominator of 
at-risk women. Therefore, backward prevalence projection was calculated under the 
assumption that age has a constant effect pattern and the stability of health care-related 
factors (e.g. availability, affordability, accessibility). The hysterectomy probability was 
derived from the hysterectomy rate by using hysterectomy probability, 𝑞(ℎ) = 1 −
e−5r(h) as used in a previous study from New South Wales of Australia. 222   
Here, r(h) stands for hysterectomy rate by five year age groups. The 95% Confidence 
Interval (CI) for prevalence (P) was calculated using the following formula: CI=P±1.96 × 
(√P(1-P)/n) where (n) stands for the population size. The adjusted uterine cancer rate was 
calculated by removing the hysterectomized women from the population at risk 
(denominator). The adjusted uterine cancer incidence rate was compared to the pre-
adjustment rate using 95% confidence intervals. SAS statistical software was used in the 
analysis (SAS version 9.4 SAS Institute Inc., Cary, NC). 
Details of uterine cancer incidence rate calculations are included in our previous chapters.   
  
 
64 
Result:  
There were 1040 hysterectomy cases in the Gharbiah region during the period of 2013 
and 2014. The total crude incidence rate of hysterectomy was 26.3 per 100,000 women 
[95% CI (24.7-27.9)]. The age-specific rate of hysterectomy was highest in the age 
groups (40-49) and (50-59) by rates of 112.2 and 109.7 per 100,000 women, respectively, 
(Table 16). The age-standardized rate (ASR) of hysterectomy was 30.4 and 95% CI was 
(28.5-32.2) per 100,000. 
Table 16: Crude Incidence Rate of hysterectomy by age group (/100,000), Gharbiah 
2013-2014 
AGE Hysterectomy 
Cases 
Incidence 
Rate per 
100,000 
95% CI 
<40 115 3.94 3.27 4.71 
40-49 522 112.25 102.93 122.19 
50-59 346 109.67 98.56 121.68 
60-69 47 28.69 21.34 37.80 
>=70 10 10.98 5.64 19.48 
Total 1040 26.30 24.74 27.93 
 
The estimated prevalence of hysterectomy was 13.1 per 10,000 women and 95% CI was 
(12.65-13.66). The age group of 45-49 had the highest prevalence of 74.8 per 10,000 
women. The prevalence of hysterectomy among women in Gharbiah increased with age 
to the peak in the age group of 45 to 49 years then gradually decreased in older women 
(Table 17).   
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Table 17: The projected prevalence of Hysterectomy in the women population of 
Gharbiah, Egypt 1999-2010 
Age groups 
Hysterectomy 
prevalence per 10,000 
95% CI 
15-19 0.1 0.03 0.36 
20-24 0.1 0.04 0.37 
25-29 2.1 1.54 2.92 
30-34 4.6 3.54 5.87 
35-39 13.8 11.95 15.94 
40-44 39.3 36.00 42.98 
45-49 74.8 69.89 80.13 
50-54 67.7 62.67 73.17 
55-59 32 27.92 36.70 
60-64 16.1 12.91 20.13 
65-69 18.4 14.39 23.59 
70-74 6.4 3.88 10.58 
75+ 4.5 2.45 8.31 
Total 13.1 12.65 13.66 
 
After adjusting for the hysterectomy cases in the population at risk, the uterine cancer 
incidence rate was not affected significantly in all age groups. The total crude rate of 
uterine cancer after adjustment for hysterectomy was 2.79 and 95% CI (2.58-300) per 
100,000 compared to almost the same rate (2.78 per 100,000 women) before the 
adjustment (Table 18).  
Table 18: Uterine cancer incidence rate before and after adjustment for 
hysterectomy by age group Gharbiah, 1999-2010 
    Before Adjustment After Adjustment 
AGE Cases Crude Rate 
per 100,000 
95% CI Crude Rate 
per 100,000 
95% CI 
<40 33 0.19 0.13 0.26 0.19 0.13 0.26 
40-49 82 2.94 2.35 3.63 2.96 2.37 3.65 
50-59 237 12.52 11.00 14.19 12.59 11.06 14.27 
60-69 217 22.07 19.28 25.16 22.11 19.31 25.20 
>=70 91 16.65 13.49 20.34 16.66 13.50 20.36 
Total 660 2.78 2.58 3.00 2.79 2.58 3.00 
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Moreover, no significant differences were seen for pre- or post-menopausal women 
regarding crude incidence rates of uterine cancer after adjustment for hysterectomy, 
(Table 19). 
Table 19: Uterine cancer crude incidence rate before and after adjustment for 
hysterectomy by menopausal status, Gharbiah, 1999-2010 
    Before Adjustment After Adjustment 
Menopause  Cases Crude Rate LL UL Crude Rate LL UL 
Pre-menopause 115 0.57 0.47 0.68 0.57 0.47 0.68 
Post-menopause  545 15.92 14.63 17.30 15.98 14.68 17.36 
Total 660 2.78 2.58 3.00 2.79 2.58 3.00 
 
The incidence rate of uterine cancer did not change significantly after adjusting for the 
projected hysterectomy prevalence [pre-adjustment IR= 2.78, 95% CI (2.85-3.00), post-
adjustment IR=2.79 95% CI (2.58-3.00)]. The incidence rate of uterine cancer could be 
significantly impacted to become IR=3.25 95% CI (3.01-3.51) if the current observed 
prevalence would increase by 110 times. 
  
  
 
67 
Discussion:  
This study has revealed interesting findings. First, women in Gharbiah have a low 
incidence rate of hysterectomy. Second, uterine cancer incidence rates did not change 
after adjusting for hysterectomy in this population. Third, based on the uterine cancer 
incidence, the observed uterine hysterectomy prevalence would need to be 110 times the 
current number of hysterectomy cases to have a significant impact on the uterine cancer 
incidence.  
This study showed that the crude and ASR of hysterectomy rates in Gharbiah were 
significantly lower than the respective rates reported from other countries. For example, 
in the U.S. the ASR of hysterectomy was 500 per 100,000 women in 2000-2004. 217 In 
Germany, the ASR of hysterectomy was reported as 362.9 per 100,000-person year in 
2005-2006. 125 However, other developed countries showed hysterectomy incidence rates 
of 370 and 120 per 100,000 women in Italy and Norway, respectively. 223,224 Based on the 
available data from Africa, the hysterectomy rate was very low compared to rates in 
developed countries. For example, the hysterectomy incidence rate was 5 per 100,000 
women in rural areas of Kenya in 1996. 225 while the ASR of hysterectomy in our study 
from Egypt is 30.4 per 100,000. The difference between hysterectomy ASRs in 
developed and developing countries could be attributed to differences in fertility rates as 
well as variation in availability of health care services and reliability of medical records 
and diseases registries. The highest age-specific rates of hysterectomy in this population 
were observed in the same age groups of high age-specific rates in developed countries 
[(40-49) and (50-59)]. 226  
  
 
68 
 These findings and observations regarding the low incidence of hysterectomy in this 
population in Egypt were confirmed by the results of our calculation of the prevalence 
rate to estimate the denominator of at-risk women. For example, the prevalence rate of 
hysterectomy in this population was 0.13% compared to prevalence of 6.9% in rural areas 
of India and 16.9% in the U.S. 227,228 A hospital-based study from Ain Shams University 
hospital in Cairo showed an increment in admissions numbers of patients requiring 
hysterectomy surgery by comparing hospital admission rates of 1995-1996 to the rate in 
2000. 212 Unfortunately, there is a scarcity of studies of hysterectomy prevalence and 
incidence in Africa and developing countries in general. Therefore, it is difficult to 
document changes in hysterectomy trends over time.  
Regarding the second observation of the insignificant impact of hysterectomy on uterine 
cancer incidence in this study, previous studies from the U.S. showed that adjustment for 
hysterectomy prevalence increased the overall age-adjusted endometrial cancer incidence 
rate from 29.2 per 100,000 to 48.7 per 100,000 i.e. increase in rate by 66.8% during the 
period 1992-2000. 127 Furthermore, several studies found that failure to adjust for 
hysterectomy prevalence resulted in distortion of uterine cancer rates based on age, race, 
and place of residence in the United State. 125,128,229 In Germany, corrected uterine cancer 
incidence rate after adjusting for hysterectomy prevalence led to a 20% increase in 
incidence. 230 Moreover, hysterectomy prevalence has different impacts on uterine cancer 
incidence rates among different countries. For example, the relative change in uterine 
cancer incidence rates after adjustment for hysterectomy prevalence was higher in the 
U.S. compared to some European countries. 230 Our study showed that the low prevalence 
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of hysterectomy in the study had no significant impact on the uterine cancer incidence 
rate in Gharbiah, Egypt. 
The results of our study revealed that hysterectomy procedures are not as common as 
presumed based on clinical impressions. The hysterectomy prevalence in our study 
population was not high enough to influence uterine cancer incidence rates. There are 
multiple factors that might have contributed to the results. There is a possibility that not 
all cases of hysterectomy were recorded or reported due to poor reporting, inadequate 
record storage, or illegal undocumented practices. However, the significant impact of 
hysterectomy on uterine cancer incidence rate in this population did not appear until the 
observed prevalence was multiplied by 110. Therefore, it is highly unlikely that even 
with underreporting of hysterectomy that uterine cancer rate is underestimated in this 
population.  
In addition, there are certain factors that could influence hysterectomy rates, such as 
availability and affordability of health care facilities and levels of socioeconomic status. 
231,232 Furthermore, knowledge and attitude about hysterectomy influence decision-
making regarding hysterectomy. A Swiss study found that patients’ knowledge about 
hysterectomy and different alternative treatments could help in reducing the choice of 
hysterectomy. 233 Cultural factors may also lead to acceptance or rejection of 
hysterectomy as a line of treatment. For example, in the Middle East, the uterus is 
considered an important organ for femininity and reproduction even in multiparous 
women. 234,235 The beliefs about the importance of the uterus may affect the utilization of 
hysterectomy among women and may also influence their consideration of other 
alternative non-surgical lines of treatments such as hormonal manipulation and laser 
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ablation. It is important to note that while hysterectomy rates were shown to be low in 
this study, the increasing rates of obesity in this population could result in increasing 
rates of gynecological diseases that will require a hysterectomy for treatment. 149,236,237  
The study has several strengths. The study was the first population-based investigation of 
the influence of hysterectomy on uterine cancer rates in Egypt. The availability of reliable 
data from the population-based cancer registry of Egypt on uterine cancer adds to the 
validity of the information. The study also provided useful information about the low rate 
of hysterectomy in this population in Egypt. The low rate of hysterectomy in this 
population can be extrapolated to the population of women in Egypt, as Gharbiah is 
representative of the country in terms of the population age structures, socioeconomic 
and geographic living status. The inclusion of the limited number of pathology labs in 
this study increased the opportunity for capturing the vast majority of the resected 
hysterectomy specimens during the study period.  However, the study has a few 
limitations. The limited storage capacity of the pathology labs restricted the duration of 
the study period. Therefore, there was a potential that some cases were missing. Also, the 
limited demographic and clinical variables in the pathology reports hindered the clinical 
investigation of the gynecological diseases involved in the study.  
In conclusion, this study highlights the low prevalence of hysterectomy among women in 
the Gharbiah region of Egypt and confirms the low incidence of uterine cancer in this 
population, eliminating the clinical impression that the low incidence of uterine cancer is 
due to high rate of hysterectomy. Future studies should investigate the clinical and 
demographic factors related to hysterectomy in this population for optimizing medical 
care and setting guidelines for practice. Additional research is needed to compare the 
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indication of hysterectomy in this population to populations in other developing 
countries. With the high and increasing rates of obesity in this population, investigating 
the potential increase in hysterectomy would be an interesting research topic.  
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Chapter 5:  
Discussion:  
Main finding of the dissertation:  
This project included three studies. The first study included in chapter two of the 
dissertation focused on investigating the epidemiologic and clinical characteristics of 
uterine cancer in Gharbiah and the changes in incidence rates and trend over the period 
1999-2010. This study revealed that the uterine cancer ASR was relatively low during the 
study period. However, the trend of uterine cancer increased significantly over time.  The 
second study in chapter three of the dissertation focused on the similarities and 
differences of uterine cancer incidence in rural and urban populations of Gharbiah. The 
results of this study showed that urban population of Gharbiah region has a significantly 
higher incidence rate of uterine cancer compared to the urban population of the region. 
However, the incidence rate of uterine cancer showed a significant increment in rural 
areas during the period 1999-2010. Interestingly, there were no differences in most 
clinical and demographic characteristics between the patients by place or residence (i.e. 
rural and urban Gharbiah). The third study in chapter four of the dissertation aimed at 
quantifying the impact of rate of hysterectomy on the incidence rate of uterine cancer in 
Gharbiah. The results of this study showed that the prevalence of hysterectomy was low 
in Gharbiah and that adjusting for the prevalence of hysterectomy did not impact the 
uterine incidence rate in the region.   
Cancer incidence rates vary across the world. It has been found that developed countries 
have higher incidence rates compared to the rates in developing countries. The variations 
among the cancer risk factors across different countries may have influence on the 
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variations of uterine cancer incidence rates. The known risk factors of uterine cancer have 
a prominent distribution among women in developed countries compared to developing 
countries. Cancer patients are traditionally exposed to the risk factors for long time (lag 
period) and the period ranges between 15-more than 25 years. For example, the high 
incidence of lung cancer in developed countries in the 1980s and 1990s resulted from 
high smoking rates in the 1950s and 1960s. Therefore, the higher rates of uterine cancer 
in the western countries after decades of exposure to risk factors could be repeated in 
developed countries in the near future with the current epidemiologic and nutritional 
transitions there and the emergence of risk factors. The rising and high rates of obesity 
among Egyptian women may increase the incidence of uterine cancer in Egypt in the next 
several years. Therefore, the analysis of the Gharbiah cancer registry data in the future 
can confirm or refute this hypothesis. However, it should be noted that the anticipated 
increase in uterine cancer rates in this population in the future, because of the high and 
increasing rates of obesity, may not lead to rates similar to the rates in developed 
countries.  The reason is that the current and near future cohorts of postmenopausal 
women in this and other similar middle-income populations in developing have 
experienced protective effects of high parity and other protective reproductive 
factors.238However, this protective effect during the premenopausal period may not last 
for long as young women in Egypt and other similar countries are experiencing later age 
of first childbirth, lower parity, and Western lifestyles. Moreover, some policies might be 
initiated to limit the exposure to risk factors. For instance the harmful effect of 
Tamoxifen and HRT may encourage healthcare policy makers in Egypt to adopt some 
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initiative to limit their use. Therefore, the increment in uterine cancer in Gharbiah may be 
reduced by limiting the exposure to possible risk factors.  
Urban women in Gharbiah have higher incidence of uterine cancer compared to the rural 
women. The variation in rates is consistent with the variation in risk factors across the two 
populations. The protective factors that help minimize the risk of uterine cancer in urban 
women were less prevalent in rural women. Therefore, the variations in the uterine cancer 
incidence across the two different populations of Gharbiah (rural vs urban) could provide 
stronger evidence about the association between uterine cancer and the mentioned risk 
factors for uterine cancer.  
Since the Gharbiah region has a low prevalence of hysterectomy, there was no impact on 
the estimation of the uterine cancer incidence rate. This study documented this finding and 
refuted the clinical impression and claims that the lower incidence of uterine cancer is due 
to hysterectomy.  
Future Directions and Conclusion:  
The future directions and recommendations of the research studies included in the 
dissertation could be formulated into the following directions: 
Research Studies:   
Future studies could be focused on epidemiologic, behavioral, environmental, and genetic 
research.  
It will be important to investigate the effect of nutritional and epidemiologic transitions in 
Egypt on the future of uterine cancer in this population.  It will be especially important to 
track the changes in reproductive factors related to endometrial cancer (e.g. parity and 
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contraceptive pills) among the population of Gharbiah in the future. Comparing the 
decline in parity with the changes in incidence of uterine cancer in the rural and urban 
populations in Egypt may help estimate the role of parity as a risk factor in association of 
the changing incidence rates.  
The pattern of uterine cancer observed in urban Gharbiah could also be investigated in 
urban populations in Cairo with much higher exposure to uterine cancer risk factors to 
further understand the risk factors in Egypt.  Higher rates of obesity, more Western diets, 
later age of first childbirth, and lower parity are more prevalent among women in Cairo 
than urban Gharbiah, warrants further research in Cairo.   
Investigating the socio-behavioral factors related to seeking medical care for uterine 
cancer may provide clues to the predominance of early-stage presentation of this disease 
in this population and how to utilize the results of such research for early diagnosis of 
other cancers. 
The external environmental xenoestrogens could impact uterine cancer development.239 
Therefore, it is important to explore the potential hazards of environmental factors that 
may contribute to increasing the uterine cancer rates in the future in both urban and rural 
populations.  
It will also important to investigate the possible protective genetic factors that reduce the 
incidence of uterine cancer in this population. Tracking the genomic classifications of 
uterine cancer in Gharbiah could help the understanding of disease pathways, 
carcinogenesis, and ultimately treatment of the different genomic subtypes of uterine 
cancer. 
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The previous research studies will help in understanding the nature of the uterine cancer 
in details based on the local characteristics of Gharbiah population. Therefore, 
implementing a tailored program and interventions will help to limit and prevent uterine 
cancer in Gharbiah region.  
Cancer Registration:  
The Population-based cancer registry in Gharbiah can play an important role in the future 
measurement of uterine cancer in the region. In order to observe the trend of uterine 
cancer, the cancer registry should maintain their regular process of registration to collect 
the cancer data from the entire Gharbiah region. It will be very interesting to observe the 
trend of uterine cancer after 2010 and compare it to the current study period.  
The completeness of the cancer registry records would help explore in detail the different 
important aspects of uterine cancer. Fortunately, many women with uterine cancer 
present in the early stages, however the survival rate could not predicted. Although, the 
mortality records of Gharbiah are available, linking the mortality records to the data of 
cancer registry will be essential in tracking patient survivorship.   
Improving the quality of hospital cancer registries in Gharbiah can also help improve the 
quality and completeness of the data of the population-based cancer registry. Moreover, 
the hospital cancer registries can help track patients’ records to monitor the time required 
for the diagnostic investigations and treatment.  
Medical care  
The population of Gharbiah has the potential for future increase in uterine cancer 
incidence rate. The future increase in uterine cancer incidence will definitely impose a 
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burden on the healthcare system of the region. Therefore, policy makers and healthcare 
stakeholders should closely observe the uterine cancer incidence and plan accordingly. 
Appropriate measures should be implemented to minimize the consequences of the high 
load of uterine cancer patients. Healthcare facilities should also be prepared for the 
potential increase in the volume of uterine cancer patients. It is recommended to establish 
a patient navigation system that could facilitate provision of optimal care to patients. 
Patients diagnosed at the early stages should be tracked to receive the appropriate 
treatment within reasonable time. Patients diagnosed in the rural areas should also be 
tracked for quick referral and initiation of treatment in the advanced oncology centers.  
Developing uterine cancer management protocols could help to deal with different types 
of uterine lesions. These protocols can minimize missed cases and can help in early 
detection.  
Education 
Educational efforts should be channeled into professional, patient and public education. 
Healthcare professionals should receive a continuous medical education through 
scientific programs that can keep them updated on the latest updates in managing uterine 
cancer. The survival data of uterine cancer is presently missing, so the relative efficacy of 
treatments cannot be assessed. Therefore, patients may require an appropriate health 
education in regard the uterine cancer and maintaining treatments.  Moreover, conducting 
a public health awareness campaign to maintain the high level of physical activities in the 
daily life of the public might be beneficial. Highlighting the hazards of the risk factors of 
uterine cancer that could have a positive impact on women’s health. For example, obesity 
and diabetes mellitus were considered a major health problem in Gharbiah region. 
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Therefore, it is essential to promote healthy life style to reduce the risk of chronic 
diseases that influences uterine cancer. 
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